HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
- Telehealth darling Hims & Hers Health Inc HIMS got slapped with a 34% stock crash on Monday. Novo Nordisk A/S NVO ended their relationship – and it wasn't amicable.
- 06/24/2025
|
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
- HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
- 06/24/2025
|
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
- The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
- 06/24/2025
|
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON HIMS & HERS HEALTH, INC. (HIMS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happ.
- 06/24/2025
|
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' Wegovy
- This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' “knockoff” weight-loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news.
- 06/24/2025
|
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
- It's not often that investors come across the kind of companies that can yield a multi-bagger investment over the years. Still, today, there is one name that possesses all the right components (and timing) to make it a suitable investment for those seeking to compound their wealth in the coming years.
- 06/24/2025
|
HIMS INVESTIGATION NOTICE: Hims & Hers Health, Inc. is being Investigated for Securities Fraud– Investors are Notified to Contact BFA Law (NYSE:HIMS)
- NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
- 06/24/2025
|
Why Did Hims and Hers Stock Crash on Monday?
- In this video, I will explain why Hims & Hers Health (HIMS -34.62%) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below.
- 06/24/2025
|
HIMS Stock To $25?
- Hims & Hers Health (NASDAQ: HIMS) experienced a devastating 35% stock crash on June 23, 2025, after Novo Nordisk abruptly terminated their brief partnership. The dramatic sell-off reflects not just the immediate loss of a key business relationship, but fundamental questions about the company's long-term viability in the weight-loss drug market.
- 06/24/2025
|
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
- LOS ANGELES , June 23, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2025
|
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation With the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm.
- 06/23/2025
|
HIMS INVESTIGATION ALERT: Investigation Launched into Hims & Hers Health, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
- SAN DIEGO , June 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Hims & Hers Health, Inc. (NYSE: HIMS) focused on whether Hims & Hers and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Hims & Hers investigation or if you are a Hims & Hers investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-hims-hers-health-inc-investigation-hims.html You can also contact attorneys J.C.
- 06/23/2025
|
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
- Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $41.98, signifying a -34.63% move from its prior day's close.
- 06/23/2025
|
HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law
- NEW YORK--(BUSINESS WIRE)---- $HIMS #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Why is Hims & Hers being Investigated? Hims & Hers is a telehealth company that provides consu.
- 06/23/2025
|
Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy, Faces Investor Scrutiny – Hagens Berman
- SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers' sales and “deceptive” marketing of the weight loss drug Wegovy®.
- 06/23/2025
|
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your lega.
- 06/23/2025
|
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
- Hims & Hers Health ( HIMS ) has been one of the market's standout growth stocks in recent years. The company has successfully built a direct-to-consumer health platform targeting conditions like hair loss, mental health, and more recently, weight loss—delivering very strong revenue growth and stock returns.
- 06/23/2025
|
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – HIMS
- LOS ANGELES--(BUSINESS WIRE)---- $HIMS--Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – HIMS.
- 06/23/2025
|
Why Hims & Hers Health Stock Is Crashing Today
- Shares of Hims & Hers Health (HIMS -33.67%) are imploding on Monday, down 32% as of 3:03 p.m. ET. The drop comes as the S&P 500 rose 0.8% and the Nasdaq Composite rose 0.7%.
- 06/23/2025
|
Weight Loss Woes: Hims & Hers (HIMS) Shares Under Pressure
- Hims & Hers (HIMS) shares are reeling after Novo Nordisk (NVO) severs its weight-loss drug relationship with the telehealth company. NVO claims HIMS was marketing knock-off weight loss drugs using "deceptive promotion" tactics.
- 06/23/2025
|
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON HIMS & HERS HEALTH, INC. (HIMS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 23, 2025, Novo Nordisk announced that it was.
- 06/23/2025
|
NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Losses to Contact the Firm
- RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers”). On June 23, 2025, during pre-market hours, the pharmaceutical company Novo Nordisk announced it would no longer provide Hims & Hers with direct access to its FDA-approved weight loss drug Wegovy through NovoCare Pharmacy due to.
- 06/23/2025
|
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers
- NEW YORK--(BUSINESS WIRE)---- $HIMS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Shares of Hims & Hers Health fell.
- 06/23/2025
|
US strikes Iran nuclear sites, Tesla shares rise, Hims & Hers falls
- Here are some of the stories covered on Market Catalysts for Monday, June 23. Stocks wavered on news that the US bombed Iranian nuclear sites.
- 06/23/2025
|
Novo Nordisk Ends Partnership with Hims & Hers
- The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
- 06/23/2025
|
Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation – HIMS
- NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) resulting from allegations that Hims & Hers may have issued materially misleading business information to the investing public. So What: If you purchased Hims & Hers securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti.
- 06/23/2025
|
Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More
- U.S. equities advanced at midday as oil prices declined on doubts the weekend U.S. military strikes against Iran and possible retaliation from Iran would disrupt supplies. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained.
- 06/23/2025
|
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
- Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
- 06/23/2025
|
Novo Nordisk under pressure, ends deal with Hims & Hers
- CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
- 06/23/2025
|
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
- Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
- 06/18/2025
|
These 2 Growth Stocks Are No-Brainer Buys Right Now
- When it comes to investing, sometimes you want to take a big swing. After all, it's not always the number of winners in your portfolio that power your returns, but finding a few stocks that can be massive winners over time.
- 06/16/2025
|
2 Reasons To Double Down On Hims & Hers Ahead Of August
- I expected Hims & Hers' stock to break $50, and now I'm buckling up for another rally, with EMAs stacked bullishly at the moment. The company's partnership with Novo Nordisk and the ZAVA acquisition for European expansion should drive the next leg of growth. Wegovy sales and potential cheaper Ozempic offerings are set to boost revenue, with subscriber growth and ARPU at record highs despite macro headwinds.
- 06/16/2025
|
Hims & Hers: An Excellent Subscription Business
- Hims & Hers offers a high-growth, recurring subscription telehealth business with strong user and revenue growth, expanding into multiple health segments. It is the market leader in telehealth easily outpacing its competition. The trend among millenials and Gen Z patients towards digital health should ensure Hims sustaining its pole position.
- 06/14/2025
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 06/13/2025
|
These 24 Stocks Are Ripe for a Short Squeeze
- With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
- 06/12/2025
|
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
- Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
- 06/12/2025
|
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market
- Hims & Hers Health's acquisition of ZAVA fast-tracks its entry into Europe's weight-loss market, expanding its subscriber base by 54%. The deal is attractively priced, non-dilutive, and leverages ZAVA's established infrastructure and regulatory expertise across four major European countries. Hims' proven GLP-1 strategy in the U.S. positions it to address Europe's unmet demand for affordable, personalized weight-loss solutions via telehealth.
- 06/11/2025
|
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
- In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
- 06/10/2025
|
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell?
- Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
- 06/10/2025
|
Hims & Hers says its weight-loss business can grow as US market changes
- Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in the U.S.
- 06/10/2025
|
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
- Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 06/09/2025
|
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
- Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (HIMS 6.96%) may finally be succeeding in cracking the code.
- 06/08/2025
|
Is Hims & Hers Health a Smart Buy Right Now?
- When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in artificial intelligence (AI). Sure, stocks such as Palantir Technologies or CoreWeave remain red-hot in a strong technology sector.
- 06/07/2025
|
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
- Telehealth has gone through a major boom-and-bust cycle. One promising stock emerging from the bust is Hims & Hers (HIMS 6.96%).
- 06/07/2025
|
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
- Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
- 06/05/2025
|
Hims & Hers Stock: Buy the Dip or Wait It Out?
- One of the most exciting growth stories in the market is that of Hims & Hers Health Inc. NYSE: HIMS. This company has combined the growth and efficiency aspects of the technology sector with the safety and stability of the medical sector.
- 06/05/2025
|
Hims & Hers Goes on a Buying Spree
- Hims & Hers (HIMS -1.76%) is using some of its recent $1 billion capital raise to buy ZAVA, a European healthcare company. In this video, Travis Hoium explains why this will keep the company's revenue growing at an incredible pace.
- 06/05/2025
|
Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst
- Hims & Hers Health, Inc. HIMS on Tuesday agreed to acquire ZAVA, a European digital health platform. The deal terms were not disclosed.
- 06/04/2025
|
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
- Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
- 06/04/2025
|
Why Is Hims & Hers Health (HIMS) Up 10.6% Since Last Earnings Report?
- Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
- 06/04/2025
|
2 Incredible Growth Stocks to Buy Hand Over Fist
- The most explosive returns in 2025 aren't coming from household names or blue chip stalwarts. Instead, they're emerging from companies at the bleeding edge of technological disruption, where visionary business models are finally reaching commercial viability.
- 06/04/2025
|
Hims & Hers stock price jumps: Telehealth company acquires Zava, picking up over a million Europe customers
- American telehealth company Hims & Hers Health announced on Tuesday that it will be acquiring Zava, a leading European digital health company in an all cash acquisition set to close in the second half of 2025. Following the announcement, Hims' stock price (HIMS) jumped 5.8% in premarket trading.
- 06/03/2025
|
Which Telehealth Stock Should You Be Targeting?
- Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform.
- 06/03/2025
|
Live Nasdaq Composite: Markets Lack Conviction Amid Trade Deal Uncertainty
- Live Updates Live Coverage Updates appear automatically as they are published. Nuclear Focus 12:00 pm by Gerelyn Terzo Wall Street firm BMO Capital Markets has initiated coverage of nuclear stock Uranium Energy (NYSE: UEC) with a “buy” rating and price target of $7.75 attached, reflecting upside potential of approximately 29% before today’s gains. BMO analysts are bullish on the stock in response to President Trump’s plan to ramp up U.S. production of nuclear power in the coming decades. Uranium Energy stock is rallying 11.1% today alongside broader gains in the nuclear power sector. Broader Market Bulls 10:28 am by Gerelyn Terzo Deutsche Bank has joined a growing list of Wall Street firms in recalibrating its 2025 S&P 500 forecast. Led by analyst Binky Chadha, who notably held an ambitious 7,000 target for the broader market index earlier in 2025, the firm has now elevated its year-end S&P 500 projection to 6,550 from a previous 6,150 estimate. This upward revision is viewed as a positive indicator for both overall market trajectory and the prospects of trade deals, suggesting an upside potential of 10% for the S&P 500 from current levels. The Nasdaq Composite is up 0.44%. This article will be updated throughout the day, so check back often for more daily updates. The markets remain uncertain as trade-related setbacks continue to loom. After eking out a slight gain on Monday, the markets are showing little direction today as investors await further trade deal progress. Reflecting caution, the Organization for Economic Co-operation and Development (OECD) lowered its growth outlook for the U.S. economy to 1.6% and 1.5% for 2025 and 2026, respectively. Technology stocks are barely higher as a sector, delivering a nearly flat performance for the Nasdaq Composite. Meta Platforms (Nasdaq: META) has inked a 20-year power-purchase deal with Constellation Energy (NYSE: CEG), securing electricity from the utility’s Illinois plant. This landmark deal marks the first direct partnership between a major tech company and the nuclear power industry. Large technology companies are hunting reliable access to the U.S. electricity grid, driven by the rapidly increasing energy demands of their AI-powered data centers. CEG shares are soaring 6%, while META stock is flat. Here’s a look at market performance this morning: Dow Jones Industrial Average: Up 26.87 (+0.06%) Nasdaq Composite: Down 11.54 (-0.06%) S&P 500: Down 3.37 (-0.06%) Market Movers Automaker Ford (NYSE: F) experienced a 16.3% jump in sales last month compared with year-ago levels. The strong performance was fueled by an employee pricing program that Ford rolled out to offset the impact from tariffs and higher vehicle sticker prices. Dollar General (NYSE: DG) is rising 13.5% today after reporting better-than-expected Q1 financial results, including strong sales. The discount retailer also raised its full-year outlook, a move that is being cheered by the markets. Hims & Hers Health (NYSE: HIMS) is up 14% in today’s trading session after announcing its acquisition of a European digital health platform. The post Live Nasdaq Composite: Markets Lack Conviction Amid Trade Deal Uncertainty appeared first on 24/7 Wall St..
- 06/03/2025
|
S&P 500 (NYSEARCA: SPY) Live: Broader Markets Stall on Trade Deal Worries
- Live Updates Live Coverage Updates appear automatically as they are published. Wall Street Turns Bullish on UEC 12:06 pm by Gerelyn Terzo BMO Capital Markets has added nuclear power stock Uranium Energy (NYSE: UEC) to its coverage universe, taking a bullish view with a “buy” rating and $7.75 price target, suggesting further runway for gains. BMO’s optimism stems from President Trump’s plan to bolster U.S. nuclear energy production over the next few decades. Uranium Energy stock has climbed 11.1% higher today, amidst broader momentum within the nuclear power industry. S&P 500 Forecast 10:23 am by Gerelyn Terzo Deutsche Bank is the latest Wall Street firm to revise its 2025 S&P 500 forecast. Deutsche analyst Binky Chadha, who in early 2025 had a whopping 7,000 target on the broader market index, has lifted the firm’s S&P 500 year-end target to 6,550 from 6,150 in a positive sign for the direction of the markets and trade deals. The latest prediction suggests upside potential of 10% for the S&P 500. This article will be updated throughout the day, so check back often for more daily updates. Uncertainty continues to grip the markets as ongoing trade-related setbacks persist. After managing only a slight gain on Monday, equities are showing little clear direction today, with investors largely holding their breath for further developments on trade agreements. Reflecting this cautious sentiment, the Organization for Economic Co-operation and Development (OECD) has trimmed its growth projections for the U.S. economy, forecasting 1.6% for 2025 and 1.5% for 2026. The SPDR S&P 500 ETF (SPY) is up 0.03%. In a notable development, Meta Platforms (Nasdaq: META) has finalized a two-decade power-purchase agreement with Constellation Energy (NYSE: CEG), securing electricity from the utility’s Illinois plant. This first-mover deal represents the first direct partnership between a major tech company and the nuclear power industry. Across the sector, large technology firms are actively seeking dependable access to the U.S. electricity grid, a necessity intensified by the rapidly escalating energy demands of their AI-powered data centers. Constellation Energy shares are surging 6% today, while Meta stock remains flat. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Down 54.45 (-0.13%) Nasdaq Composite: Up 72.65 (+0.38%) S&P 500: Up 4.61 (+0.08%) Market Movers Automaker Ford (NYSE: F) saw a robust 16.3% increase in sales last month compared to figures from a year ago. This impressive performance was largely driven by an employee pricing program that Ford implemented to counter the effects of tariffs and higher vehicle sticker prices. Meanwhile, discount retailer Dollar General (NYSE: DG) is enjoying a 13.5% jump today after reporting better-than-anticipated first-quarter financial results, including strong sales figures. The company also uplifted its full-year outlook, a move that’s clearly being well-received by the markets. Lastly, Hims & Hers Health (NYSE: HIMS) is up 14% in today’s trading session following its announcement of the acquisition of a European digital health platform. The post S&P 500 (NYSEARCA: SPY) Live: Broader Markets Stall on Trade Deal Worries appeared first on 24/7 Wall St..
- 06/03/2025
|
Top Stock Movers Now: Dollar General, Hims & Hers, Bumble, and More
- U.S. equities rose at midday as the markets continued to wait for more information about possible U.S. trade deals. The Dow Jones Industrial Average, S&P 500, and Nasdaq were slightly higher.
- 06/03/2025
|
Hims & Hers Expands in Europe With Acquisition of ZAVA
- Hims & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed.
- 06/03/2025
|
Hims expands into Europe with Zava acquisition
- CNBC's Brandon Gomez reports on the latest news regarding Hims.
- 06/03/2025
|
The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
- Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
- 06/03/2025
|
Why Hims & Hers Health, Inc. (HIMS) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 06/03/2025
|
Hims & Hers expands into Europe with Zava acquisition
- Hims & Hers (NYSE:HIMS), a leading US-based health and wellness platform, is expanding into Europe via its acquisition of telehealth platform and online pharmacy Zava. The company said the acquisition will expand its footprint in the UK and launch the company in Germany, France and Ireland, with additional markets expected soon.
- 06/03/2025
|
Hims & Hers stock rockets on news of European launch
- Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform.
- 06/03/2025
|
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
- Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
- 06/03/2025
|
Hims & Hers: Still Huge Potential Ahead
- Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.75 in February but has since settled at $49.47. Financials reveal a 111% YoY revenue increase to $586 million and a 77.5% rise in net income to $49.5 million.
- 06/03/2025
|
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 06/02/2025
|
Hims & Hers: Peptide And Short Squeeze Are Coming!
- Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1, positioning itself as a leader in the biohacking and longevity markets. The company's strategic moves—acquiring a peptide facility, partnering with Novo Nordisk, and investing in AI-driven customization—create a strong competitive advantage and growth runway. With short interest at 34% and legal risks largely resolved, the stock is primed for a potential short squeeze and upward momentum, especially as valuation remains low.
- 05/31/2025
|
What's Happening With HIMS Stock?
- Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce. This move comes as the company responds to a U.S. ban, effective May 22nd, on the production of mass copies of the weight-loss medication, Wegovy.
- 05/31/2025
|
Hims to cut 4% of workforce amid ban on weight-loss drug copies
- Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
- 05/30/2025
|
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
- HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.
- 05/30/2025
|
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
- Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialties, and global expansion, aiming for significant top-line and EPS growth.
- 05/29/2025
|
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
- HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
- 05/28/2025
|
3 Surprising Stocks That Have More Than Doubled in 2025
- This year has had its ups and downs on Wall Street, but some investments are rolling. There are 14 stocks with market caps north of $1 billion that have more than doubled so far in 2025 -- and some of the names will surprise you.
- 05/27/2025
|
Cautious? Risky? Our Volatility Scorecard Can Help
- Subscribers to Chart of the Week received this commentary on Sunday, May 11.
- 05/27/2025
|
Hims & Hers Health: New Guidance Creates Huge Risk For Shorts
- Hims & Hers Health continues to fire on all cylinders as a business, growing at extraordinary rates while also improving its margins. Today, I will offer a unique and simplified view of the business based on its recently announced, and very important, deal with Novo Nordisk. In short, based on Hims multi-product and multi-brand platform, which has generated sustained free cash flow for years now alongside healthy growth, I believe there's still upside ahead.
- 05/25/2025
|
Avoid These Dividend Disasters Before It's Too Late
- Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
- 05/23/2025
|
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. “We are always looking for long-term, sustainable ways to increase access to care for our customers,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “This is another example of how.
- 05/22/2025
|
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
- When investors choose to risk their capital in an individual company, they must be aware that the stock market isn't the one-sided machine it used to be a few decades ago. Thanks to the flow of information and availability in the digital space, today's market has become more interconnected than ever before.
- 05/22/2025
|
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock?
- Hims & Hers (HIMS -5.42%) has put investors on a roller coaster ride in 2025.
- 05/22/2025
|
5 Single-Stock ETFs That Doubled in a Month
- We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
- 05/21/2025
|
Hims & Hers: After A Bout Of Uncertainty, Upside Remains
- Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% year-over-year and operating leverage improving. The business model's shift to a subscription platform with personalized care unlocks significant long-term free cash flow and expansion opportunities. Management's guidance and execution support a path to $6.5B in revenue by 2030, with my valuation thesis still intact and suggesting undervaluation.
- 05/21/2025
|
Hims & Hers Stock Chart Points to Strong Bullish Continuation
- Hims and Hers, Inc. NYSE: HIMS shows strongly bullish signs that begin and end with the stock price action. It reflects volatility, but the bias is upward with rising support and the most recent swing, a bullish rebound, looks very strong within the pattern.
- 05/20/2025
|
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
- Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
- 05/19/2025
|
Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?
- HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
- 05/16/2025
|
Buy Amazon (AMZN), Shopify (SHOP) and Hims & Hers (HIMS) in May And Hold Forever
- There's a well-known saying in the investing world, which advises investors to “sell in May and go away.
- 05/16/2025
|
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
- Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
- 05/16/2025
|
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
- Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though reliance on GLP-1 drugs and competition are key risks.
- 05/16/2025
|
Hims & Hers Health, Inc. (HIMS) is a Great Momentum Stock: Should You Buy?
- Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 05/14/2025
|
Top Health & Fitness Stocks to Buy for the Wellness Boom
- The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
- 05/14/2025
|
Hims & Hers stock price nears crucial level: is it a buy or sell?
- Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue in the coming years. HIMS shares surged by almost 16% on Tuesday, reaching its highest level since February.
- 05/14/2025
|
Cautious? Risky? Our Volatility Scorecard Can Help
- Subscribers to Chart of the Week received this commentary on Sunday, May 11.
- 05/13/2025
|
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
- Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potential to upwards of $300 per share in a bullish case scenario (2030 DCF model).
- 05/12/2025
|
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
- Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
- 05/12/2025
|
Hims & Hers: Still Undervalued For These 2 Reasons
- Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'
- 05/12/2025
|
Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth
- Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a target of $6.5B+ revenue and $1.3B+ adj. EBITDA by 2030, driven by TAM penetration, new specialties, and AI integration.
- 05/12/2025
|
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
- Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testosterone and menopause support, are driving subscriber growth and higher revenue per subscriber.
- 05/12/2025
|
Massive Hims & Hers News: $1 Billion on AI and Acquisitions
- Hims & Hers (NYSE: HIMS) stock has been on fire in 2025, and the company just got more great news after upsizing a $450 million convertible debt offering to up to $1 billion. The growth of Hims & Hers should move overseas, and artificial intelligence will play a bigger role in its future now.
- 05/10/2025
|
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 05/09/2025
|
Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.
- 05/08/2025
|
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
- If short sellers were hoping for a flop from Hims & Hers Health Inc. HIMS, they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S NVO.
- 05/08/2025
|
Hims & Hers: The Road To Blue Chip Status
- Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team.
- 05/08/2025
|
Hims & Hers Soars Again--Explosive Growth Meets Lofty Expectations
- Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo Nordisk partnership. Despite trading at a high valuation, technical indicators suggest continued short-term momentum, with potential for a pullback near February highs. The company's evolution from a telehealth startup to a health-tech giant showcases its strong growth, profitability, and expanding service offerings.
- 05/08/2025
|
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant.
- 05/08/2025
|
Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply pe.
- 05/08/2025
|
Hims & Hers Has a Superpower in Healthcare
- Hims & Hers (HIMS 5.21%) CEO Andrew Dudum isn't interested in taking insurance onto his platform, and that shows how disruptive the company could be. This could be the next great growth stock if Dudum's plans to aggregate demand play out as hoped.
- 05/08/2025
|
Hims & Hers Health Shocks Investors With a Long-Term Forecast, but Is the Stock a Buy?
- Following the company's first-quarter earnings report, shares of Hims & Hers Health (HIMS 5.21%) opened the following day considerably lower, only to sprint higher once trading began. This action is just one example of why the stock is a bit of a divisive name among investors.
- 05/08/2025
|
Hims & Hers: 2030 Guidance Indicates Big Upside
- Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 2025 and 2030, Hims & Hers could be undervalued by up to 62%. Apart from the guidance, the company needs to achieve growth rates in the mid-teens% to justify the current valuation.
- 05/07/2025
|
Surging Earnings Estimates Signal Upside for Hims & Hers Health (HIMS) Stock
- Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 05/07/2025
|
Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade)
- Hims & Hers Health, Inc. Q1 results beat the Street's expectations, as I anticipated in February. The company reaffirmed FY 2025 guidance and increased the EBITDA range for the year. That said, I believe the rally on May 6 was driven by the high short interest and not by fundamentals. The availability of Eli Lilly and Novo Nordisk weight loss drugs on the Hims platform is significant, but the easing of drug shortages could affect Q2 subscriber numbers.
- 05/07/2025
|
Hims & Hers Shows It's More Than Just GLP-1 Drugs
- Hims & Hers Health (HIMS) released first-quarter earnings after the closing bell on Monday and saw shares surge on the robust numbers.
- 05/07/2025
|
Hims & Hers Health: Healthcare Disruptor Building A Durable Moat (Initiate With Buy)
- Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel effect driven by machine learning and big data analytics. Risks include the untested business model, potential legal issues, and the complexity of international expansion, but the growth potential presented far outweighs these concerns.
- 05/07/2025
|
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth
- Hims & Hers (HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a short squeeze likely helped, which Travis Hoium discusses in this video.
- 05/07/2025
|
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
- Investors are buying Hims & Hers Health (HIMS 19.77%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of Eli Lilly (LLY -6.21%) and Novo Nordisk (NVO -4.31%), the latter of which is a Hims & Hers partner now.
- 05/06/2025
|
Options Bulls Blast Surging Telehealth Stock After Earnings
- Hims & Hers Health Inc (NYSE:HIMS) beat top- and bottom-line estimates for the first quarter, with net profits seeing a 300% jump.
- 05/06/2025
|
2 Reasons Hims & Hers Will Break $50s - Buy Post Earnings
- Hims & Hers Health, Inc. impressed with strong Q1 earnings, subscriber growth, and a promising partnership with Novo Nordisk, but didn't guide as well as we all hoped. The two reasons I'm buying are 1. The partnership with Novo should expand to include Ozempic and 2. Oral pill approval from the FDA should be achieved and boost financials. I think we're still at the start of Hims' comeback story, and the stock is still cheap considering its upside potential.
- 05/06/2025
|
Hims & Hers stock jumps after blowout quarter, long-term guidance stuns Street
- Shares of Hims & Hers Health (HIMS) surged 10% on Tuesday morning after the telehealth company posted first-quarter results that far surpassed Wall Street expectations and unveiled an ambitious roadmap targeting $6.5 billion in revenue by 2030. Revenue in the quarter more than doubled to $586 million, up 111% from a year earlier and well ahead of analysts' average estimate of $538.9 million.
- 05/06/2025
|
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
- The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
- 05/02/2025
|
Hims & Hers: Revolutionizing Healthcare
- The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs, significantly boost revenue and deepen customer relationships. Embracing AI and peptide therapies positions Hims & Hers for future growth, though regulatory compliance and reliance on third-party suppliers pose risks.
- 05/01/2025
|
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
- MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
- 05/01/2025
|
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
- Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
- 04/30/2025
|
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
- Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
- 04/30/2025
|
Live Nasdaq Composite: Markets Stand Still on Tariff and Tech Tussle
- Live Updates Live Coverage Has Ended Trade Deals 3:06 pm by Gerelyn Terzo Commerce Secretary Howard Lutnick reportedly revealed that the U.S. has secured one trade deal, keeping most of the details close to the vest except to say that the White House is awaiting a green light from some unnamed country. The Dow Jones Industrial Average rose as much as 300 points in response for a 0.84% gain, while the Nasdaq Composite and S&P 500 are holding similar gains. Narrow Range 12:34 pm by Gerelyn Terzo The markets are managing slight gains across the Nasdaq Composite, S&P 500 and Dow Jones Industrial Average despite the absence of greater details on any global trade deals. Of the S&P 500, Baird investment strategist Ross Mayfield is cited by CNBC as saying, “I think [stocks are] probably trapped in a in a pretty tight range here,” pointing to a range of 5,100-5,700. “I think we can bounce around there for quite a while in kind of some volatile, choppy trading. Until we get some resolution on the trade front, I don’t think much else matters,” he added. Consumer Weakness 11:03 am by Gerelyn Terzo The stock market averages are currently all moving higher despite some weaker than anticipated economic data. The U.S. consumer has long been credited with upholding the economy throughout the one-two punch of inflation and higher interest rates. Now the tariffs could be the straw that broke the camel’s back, as consumer confidence shows signs of waning. The Consumer Confidence Index published by the Conference Board sank to a reading of 86 in April, a drop of nearly 8 points from the prior month and below economist estimates calling for 87.7. A separate index that reflects consumer sentiment over the next six months fell by a steep 12.5 points to a reading of 54.4, its worst level in over a decade. The Bureau of Labor Statistics revealed that March job postings dropped to their lowest level in about six months. Tariffs, Earnings and Tech 10:00 am by Gerelyn Terzo The markets continue to trade mixed this morning on tariff deal ambiguity as Q1 earnings results pour in. Stocks are weighing earnings results and a lack of certainty on the tariff deal front while tensions have emerged between Amazon (Nasdaq: AMZN) and the White House over tariff-related costs. Magnificent Seven stocks are mixed, with Amazon and Alphabet (Nasdaq: GOOGL) trading in the red while Nvidia (Nasdaq: NVDA) benefits from a Wall Street endorsement. Hims & Hers HEalth (Nasdaq: HIMS) is soaring by 24% today on news of a deal to sell weight loss drug phenom Wegovy on its e-commerce platform. The markets are holding out for more tariff deal progress, digging in their heels and nearly standing still in the meantime. The three major stock market averages are moving fractionally in either direction, with the Nasdaq Composite posting slight declines alongside the S&P 500 while the Dow Jones Industrial Average is eking out modest gains. Sectors of the economy are evenly split between red and green, with real estate moving higher and consumer discretionary stocks headed lower. Amazon (Nasdaq: AMZN) is getting some unwanted attention after the White House took aim at the tech giant, calling its reported plans to list tariff cost impacts on its site as a “hostile and political act.” Big 3 automaker General Motors (NYSE: GM) reported better-than-expected quarterly results while reassessing its full-year outlook, sending the stock lower by 1.5%. GM and the auto sector have targets on their backs at the height of the tariff wars, in response to which the former Dow component has suspended all share buyback programs. The White House has affirmed its plans to provide tariff relief to the auto sector. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Up 138.11 (+0.36%) Nasdaq Composite: Down 67.15 (-0.40%) S&P 500: Down 10.23 (-0.19%) Earnings & Analyst Calls Coca-Cola (NYSE: KO) surpassed Q1 expectations on the top and bottom lines and is keeping its full-year guidance intact amid expectations that it will be able to manage any tariff-related fallout, including rising aluminum costs. Rival company PepsiCo (NYSE: PEP) recently lowered its earnings forecast due to the tariff impact. Evercore ISI has reiterated its “outperform” rating on Apple (Nasdaq: AAPL) stock with a $250 price target, suggesting the company’s strategies should help it to offset any impact from the tariff frenzy. Piper Sandler has reiterated its “overweight” rating on Nvidia (Nasdaq: NVDA), saying that the China tariff uncertainties notwithstanding, the AI leader’s strong market relationships give the stock a place in the analyst firm’s top large cap pick universe. UBS has reiterated its “buy” rating on Amazon (Nasdaq: AMZN) but lowered the price target to $253 from $272, owing to what it described as “potential demand destruction.” The post Live Nasdaq Composite: Markets Stand Still on Tariff and Tech Tussle appeared first on 24/7 Wall St..
- 04/30/2025
|
Hims & Hers Stock Soars on Novo Nordisk Collaboration
- Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
- 04/30/2025
|
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
- Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
- 04/30/2025
|
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
- Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 04/30/2025
|
S&P 500 (VOO) Live: Trump Administration Blasts Amazon.com, and the S&P 500 Tumbles
- Live Updates Live Coverage Has Ended S&P 500 Extends Its Winning Streak 4:18 pm The S&P 500 closed up 0.6% for Tuesday, extending its winning streak to six straight days. Trade Talks Keep S&P 500 Moving Higher 1:51 pm “Ask, and ye shall receive.” Investors for example have been asking a lot lately, for proof that President Trump’s tariffs threats will result in trade deals that can benefit the U.S. economy. Today, Treasury Secretary Scott Bessent announced that the conclusion of a trade deal with India is almost set now, with deals with both Japan and South Korea likely to follow in short order. That’s exactly what investors wanted to hear. The S&P 500 is now up 0.7%, and so is “the Voo.” Trump Growls, Amazon Caves 12:13 pm Well, that was quick! No sooner had the White House expressed disapproval of an Amazon plan to inform customers of how much tariffs were raising the cost of goods sold on its site, than Amazon has abandoned the plan. Amazon spokesman Tim Doyle has just tossed the idea under the proverbial bus, admitting he “considered the idea” but it “was never approved and not going to happen.” Commerce Secretary Howard Lutnick (see above) commented: “Good move,” Amazon. Tariffs Threaten Supply Chain, Wall Street Shrugs 10:57 am Gene Seroka, the executive director of the Port of Los Angeles, is warning of a “precipitous drop” in shipments from China as “major American retailers stop … all shipments from China based on the tariffs” announced by President Trump earlier this month. Despite the warning, investors have resumed buying stocks, and the S&P 500 is now in positive territory, up 0.3%. Stock markets opened lower on Tuesday, threatening to break the S&P 500’s five-day winning streak, although the market is moving back towards breakeven now. The S&P 500 opened 0.3% lower this morning, and the Vanguard S&P 500 ETF (NYSEMKT: VOO) likewise opened down 0.3%. T In political news, White House press secretary Karoline Leavitt blasted a reported plan by Amazon.com (Nasdaq: AMZN), to display the cost of wares on its site next to the amount the cost was inflated by tariffs cost, as a “hostile and political act.” Things could be worse, though. Last night, Commerce Secretary Howard Lutnick promised to “reward … companies who manufacture domestically” by reducing tariffs on foreign auto parts used to manufacture cars in the U.S. General Motors (NYSE: GM) CEO Mary Barra responded to the news by promising to “invest even more in the U.S. economy.” Ford (NYSE: F) CEO agreed that the move “will help mitigate the impact of tariffs on automakers, suppliers and consumers.” Earnings Speaking of General Motors, the automotive giant reported this morning that its Q1 profits came in at $2.78, $0.17 ahead of analyst forecasts. Commercial truckmaker Paccar (Nasdaq: PCAR) on the other hand reported profits $0.14 below forecasts. In housing, we see LGI Homes (Nasdaq: LGIH) miss badly, but paintmaker Sherwin-Williams (NYSE: SHW) beat. In airlines, Jetblue Airways (Nasdaq: JBLU) reported a $0.59 per share loss, but this was $0.02 better than the $0.61 per share loss it was expected to report. Analyst Calls Analyst action is so far muted. Swiss bank UBS upgraded cranemaker Crane (NYSE: CR) to buy. Tariffs war and “market uncertainty” notwithstanding, UBS says it’s “increasingly confident in the long-term earnings outlook and M&A opportunity” for the company. Not everyone’s so confident, however. Already this morning we’re seeing downgrades outnumber upgrades, with Stifel cutting Builders FirstSource (Nasdaq: BLDR) to neutral, Bank of America lowering ConocoPhillips (NYSE: COP), also to neutral, and TD Cowen downgrading GLP-1 drugs compounder Hims & Hers (NYSE: HIMS) to hold, citing increased competition from Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), and a lack of near-term catalysts to move the stock higher. The post S&P 500 (VOO) Live: Trump Administration Blasts Amazon.com, and the S&P 500 Tumbles appeared first on 24/7 Wall St..
- 04/29/2025
|
Hims & Hers Health: GLP-1 Deals De-Risk The Story
- Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness platform already targeted $725 million in weight-loss sales this year, without including any branded GLP-1 sales. The company's core business remains robust, with significant contributions from sexual health, dermatology, and mental health, accounting for over $1.2 billion in 2024 sales.
- 04/29/2025
|
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
- Shares of Hims & Hers Health (HIMS 25.46%) and LifeMD (LFMD 35.41%) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m.
- 04/29/2025
|
Hims & Hers stock pops on Novo Nordisk partnership
- Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
- 04/29/2025
|
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
- Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
- 04/29/2025
|
Hims & Hers partners with Novo Nordisk to sell Wegovy
- Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
- 04/29/2025
|
Hims & Hers Stock Rides Wegovy Wave Higher
- Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 22.6% at $34.92 at last glance, after news that the telehealth platform will offer Novo Nordisk's (NVO) popular weight-loss drug, Wegovy.
- 04/29/2025
|
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
- Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
- 04/29/2025
|
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
- Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
- 04/29/2025
|
HIMS stock spikes over 40%; Time to buy?
- Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform.⚈ The move positions Hims & Hers to capitalize on booming demand for weight-loss medications.
- 04/29/2025
|
Hims & Hers pact with Novo de-risks 2025 outlook, says Needham
- Hims & Hers +7.43 (+26.06%) Novo Nordisk +1.96 (+3.13%) 05 May 07 May 12 Jun
- 04/29/2025
|
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
- Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
- 04/29/2025
|
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
- Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
- 04/29/2025
|
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
- Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
- 04/29/2025
|
Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.
- The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.
- 04/29/2025
|
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
- Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally restricted from making cheaper, unapproved versions of Wegovy, with rare exceptions.
- 04/29/2025
|
Hims & Hers partners with Novo Nordisk to sell Wegovy on its platform
- Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled offering on the telehealth company's platform, the two companies said on Tuesday.
- 04/29/2025
|
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
- SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care,.
- 04/29/2025
|
Hims & Hers: Selling Options On This High-Growth Gem Could Yield 20% Or More (Rating Upgrade)
- Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put options offers a better risk/reward. Selling the August, $18-strike put options yields 27.7% annualized, providing a robust yield, and a potentially stronger entry point at a more attractive valuation.
- 04/28/2025
|
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
- Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2025
|
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
- In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14% change from the preceding trading day.
- 04/25/2025
|
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
- Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufacturing (an alternative to semaglutide) which will be able to recoup lost sales in its weight loss division after the FDA shortage of semaglutide ends. Hims trades at an appealing 18.1x EV/FY26 adjusted EBITDA, which is modest for a company growing revenue and adjusted EBITDA at a >60% y/y pace.
- 04/23/2025
|
The FDA has posted a warning about generic forms of a popular hair-loss medication often sold by major telehealth companies including Hims, Keeps and Ro
- Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects.
- 04/23/2025
|
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 04/22/2025
|
Hims & Hers: Top Pick For The Next Decade
- Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company.
- 04/21/2025
|
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
- Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
- 04/21/2025
|
Investment strategist picks 3 ‘new age' healthcare stocks to buy
- Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors.
- 04/20/2025
|
Bull of the Day: Hims & Hers Health (HIMS)
- Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
- 04/18/2025
|
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
- In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.
- 04/17/2025
|
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
- Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
- 04/17/2025
|
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it
- HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
- 04/16/2025
|
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
- In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day.
- 04/11/2025
|
Hims' Weight Loss Expansion: Real Growth or Just Hype?
- One of the more hotly debated stocks in the market, Hims & Hers Health NYSE: HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly's NYSE: LLY blockbuster weight loss drug.
- 04/10/2025
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 04/07/2025
|
Why Hims & Hers Health Stock Couldn't Beat the Market Today
- Hims & Hers Health (HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects.
- 04/02/2025
|
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
- In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
- 04/02/2025
|
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
- CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
- 04/01/2025
|
Why Hims & Hers Health Stock Soared Tuesday
- Shares of Hims & Hers Health (HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.
- 04/01/2025
|
Hims & Hers shares rise as company adds new weight-loss medications to platform
- Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
- 04/01/2025
|
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
- Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.
- 04/01/2025
|
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
- Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
- 04/01/2025
|
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
- The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $29.55, representing a +1.41% change from its previous close.
- 03/31/2025
|
Is Hims & Hers Stock Too Cheap to Pass Up?
- Hims & Hers (HIMS -8.84%) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today.
- 03/29/2025
|
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
- What goes up can come down. Investors who jumped on the Hims & Hers Health (HIMS -4.12%) bandwagon have experienced this pain first-hand.
- 03/28/2025
|
Here's why Hims & Hers stock price has crashed: buy the dip?
- Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year.
- 03/27/2025
|
Hims & Hers Health: Reaching Escape Velocity Goes Unnoticed By The Market
- I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stock drop, in my view. 2025 revenue guidance of $2.29-$2.39 billion and a 3.6x multiple on its $8.3 billion market cap suggest undervaluation. HIMS' PEG ratio of ~1 (P/E of 58 ÷ 56% growth) signals undervaluation for a high-growth company, typically seen in mature firms, not one scaling at 50%+ with 85% customer.
- 03/26/2025
|
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
- Hims & Hers Health, Inc. (HIMS) reachead $37.04 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
- 03/25/2025
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 03/25/2025
|
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
- Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and women's health, dermatology, and mental health, along with its personalized healthcare solutions, supports long-term growth potential. Strong financial performance with a 69% revenue increase in 2024, a growing subscriber base, and improved marketing efficiency highlight H&H's disciplined growth strategy.
- 03/25/2025
|
Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?
- Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/24/2025
|
Hims & Hers Health: Developing A Better Understanding
- Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a unique perspective that sheds light on what the platform does. In short, I like to call Hims an "AI-orchestrated general physician at national scale," and I'll walk us through what that means today.
- 03/20/2025
|
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
- Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.
- 03/20/2025
|
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
- Hims & Hers (HIMS) is a newfangled tele-health company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one's given the stock a heck of ride; way up and then all the way back down. More big moves could happen in the near term. Looking deeper and reading a lot of tea leaves, I envision HIMS growing from a peddler of feel-good non-essential medications into a serious player in the emerging personalized medicine field.
- 03/20/2025
|
Why Hims & Hers Stock Tumbled on Tuesday
- Hims & Hers Health (HIMS -6.95%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target on the pharmaceuticals stock in the worst way possible.
- 03/18/2025
|
Why Hims & Hers Stock Popped on Monday
- Hims & Hers Health (HIMS 3.58%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach delivered some good news for the mail-order drugs stock.
- 03/17/2025
|
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers
- MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ: RKLB) and Hims & Hers Health Inc. (NYSE: HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.
- 03/13/2025
|
Why the Market Dipped But Hims & Hers Health, Inc. (HIMS) Gained Today
- In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $34.71, marking a +0.7% move from the previous day.
- 03/11/2025
|
Why Hims & Hers Health Stock Just Popped
- Roller-coaster healthcare stock Hims & Hers Health (HIMS 5.26%), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration (FDA) on Monday.
- 03/11/2025
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 03/11/2025
|
Should You Buy Hims & Hers Stock on the Dip?
- Hims & Hers (HIMS -4.12%) is taking investors on a roller-coaster ride in 2025.
- 03/11/2025
|
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
- Hims & Hers (HIMS -4.12%) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever.
- 03/11/2025
|
3 Cold Stocks That Can Bounce Back This Week
- This past week was rough for most investors, but it was a lot harder for a handful of cascading stocks. There were nearly a dozen U.S. exchange-listed companies with market caps north of $1 billion that tumbled by at least 20% last week.
- 03/10/2025
|
Bet on DuPont Analysis & Pick 5 Quality Stocks
- Do you have more faith in DuPont analysis than simple ROE calculation? Tap Hims & Hers Health (HIMS), Blue Bird (BLBD), EMCOR Group (EME), EverQuote (EVER) and Sprouts Farmers Market (SFM).
- 03/10/2025
|
Hims & Hers: AI-Powered Healthcare Disruption
- Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company's subscriber base reached 2.2 million, growing 45% year-over-year, with 55% of subscribers using at least one personalized treatment. Hims & Hers' GLP-1 weight loss treatments contributed $225 million in incremental revenue, but regulatory and supply risks remain significant concerns.
- 03/09/2025
|
Hims & Hers to shut down dermatology business Apostrophe
- Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.
- 03/07/2025
|
Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
- Hims and Hers is shutting down the dermatology business it acquired in 2021, BI has learned. The company said it's closing skincare site Apostrophe to centralize its teledermatology offerings.
- 03/07/2025
|
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
- Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% increase in subscribers and higher average revenue per subscriber. To mitigate risk, consider selling call options against HIMS shares, leveraging high implied volatility for a favorable risk-reward proposition.
- 03/07/2025
|
This Could Be a Huge Blow to Hims & Hers Health Stock
- Hims & Hers Health (HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized telehealth options, the business has experienced tremendous growth.
- 03/07/2025
|
Why Hims & Hers Stock Just Collapsed
- Hims & Hers Health (HIMS -12.33%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas.
- 03/06/2025
|
Healthcare Stock Could Be Good 'Buy the Dip' Play
- The shares of healthcare name Hims & Hers Health Inc (NYSE:HIMS) have retreated from their Feb. 19, pre-earnings all-time high of $72.98.
- 03/05/2025
|
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
- The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
- 03/05/2025
|
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
- Hims & Hers Health, Inc. HIMS stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.
- 03/05/2025
|
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
- HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a tailwind, allowing its core personalized healthcare portfolio to shine, as observed in the double digits non-GLP-1 revenue growth. The same has been observed in the rich FY2024 performance metrics and the management's FY2025 guidance, as they seek to expand their vertically integrated healthcare offerings.
- 03/03/2025
|
Hims & Hers: A Generational Dip-Buying Opportunity
- HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While bears focus on waning GLP-1 sales, HIMS' business outside GLP-1s is still growing rapidly.
- 03/02/2025
|
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
- Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (HIMS 9.07%) plummeted following its fourth-quarter earnings report. The stock had rocketed from around $24 at the start of the year to over $70 before pulling back.
- 03/01/2025
|
Why Hims & Hers Health Stock Sank This Week
- Shares of Hims & Hers Health (HIMS 6.76%) sank 10.5% this week, according to data from S&P Global Market Intelligence. The telehealth company that sells dermatology, sexual health, and weight loss drugs directly to consumers posted strong growth for the fourth quarter of 2024 but has investors concerned over the legality of its weight loss drug compounds.
- 02/28/2025
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 02/28/2025
|
Hims & Hers: Shortage-Driven Sell-Off Appears Overdone; Buy
- Hims and Hers' stock dropped 25% due to the end of the semaglutide shortage, but the sell-off is seen as exaggerated. Despite the setback, Hims and Hers continue to show strong subscriber growth and profitability, with a 269.49% increase since December 2021. The company benefits from political support and a $5 billion market cap boost post-Super Bowl, indicating potential for explosive growth.
- 02/27/2025
|
Why Hims & Hers Stock Rebounded on Wednesday
- Hims & Hers (HIMS 5.09%) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty healthcare company on that slump, which helped Hims & Hers recover by more than 5% in mid-week action.
- 02/26/2025
|
Hims & Hers: Down 45% In 5 Days, Is The Stock Still A Buy?
- Hims & Hers Health is a promising disruptor in the $4T US healthcare market, aiming to become the most trusted health & wellness brand. Despite recent stock volatility, Hims & Hers' Q4 2024 report showed strong growth, with revenues up 95% y/y and robust 2025 guidance. The end of semaglutide compounding poses challenges, but Hims & Hers is expected to maintain growth through diversified offerings and new specialties.
- 02/26/2025
|
Wall Street's Most Wanted: 2 Highly Shorted Stocks Right Now
- Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling shares short are hoping that the price of certain stocks falls so that they can make a profit.
- 02/26/2025
|
Hims & Hers Health: Focus On The Future, Not GLP-1s
- Hims & Hers Health, Inc. reported strong growth, with Q4 sales up $80 million sequentially, yet HIMS stock fell due to GLP-1 business confusion. The online health and wellness platform guided to $2.3 billion in 2025 revenues and $300 million in adjusted EBITDA despite the FDA ending GLP-1 shortages. Hims' non-GLP-1 sales grew 43% to $1.2 billion, showing its business isn't reliant on GLP-1 sales.
- 02/25/2025
|
HIMS Stock Craters – Is It a Buying Opportunity?
- Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn't guarantee it would be able to continue selling its knockoff versions of weight-loss drugs Ozempic and Wegovy.
- 02/25/2025
|
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts
- Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter.
- 02/25/2025
|
Hims Stock Crashed After Earnings. What Went Wrong?
- In this video, I will go over the fourth-quarter earnings report from Hims & Hers (HIMS -27.60%) and explain why the stock crashed on Tuesday. Watch the short video to learn more, consider subscribing, and click the special offer link below.
- 02/25/2025
|
Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know
- Hims & Hers (HIMS -27.66%) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are concerned about the future of GLP-1s.
- 02/25/2025
|
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
- Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year.
- 02/25/2025
|
Hims & Hers CFO talks Q4 earnings
- Hims & Hers Health (HIMS) stock is dropping in extended hours upon the telehealth company's fourth quarter earnings release, topping revenue ($481.14 million vs. forecasts of $470.39 million) and total subscribers estimates (2.23 million vs.
- 02/25/2025
|
Bitcoin Concerns, SPX Upside to "$6030" & HIMS Sinks
- As Bitcoin (/BTC) falls to 3-month lows, Kevin Green points to fundamental factors that are weighing on its price activity. He says the technical setup indicates possible selling pressure remains for popular crypto asset.
- 02/25/2025
|
Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.
- Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer.
- 02/25/2025
|
Hims & Hers shares drop on doubts over weight-loss business forecast
- Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight-loss drugs.
- 02/25/2025
|
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
- I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024, with a broader weight loss strategy including oral treatments and liraglutide. I believe affordability will drive demand for Hims' weight loss products, as many overweight Americans may struggle to afford Novo Nordisk's expensive GLP-1 treatments.
- 02/25/2025
|
Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade
- Hims & Hers experienced a sell-off due to profit-taking and weaker-than-expected EBITDA margins, despite strong revenue growth. The company is projected to generate over $2 billion in revenues and $350 million in free cash flow in 2025, with no debt. While EBITDA margins have fluctuated, free cash flow remains strong, making the stock attractive at 26x forward free cash flow.
- 02/25/2025
|
Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
- Hims & Hers stock fell ~19% post-Q4 earnings despite revenue beating expectations and EPS aligning with estimates, attributed to gross margin concerns and potential dependency on GLP-1 for future growth. The company's growth remains strong, with a 95% YoY revenue increase, an expanding subscriber base, and higher revenue per subscriber, indicating robust market capture and customer loyalty. Future potential is promising with new service additions, a vast addressable market, and strategic diversification, mitigating risks from competition and regulatory changes.
- 02/25/2025
|
Hims & Hers CFO, drone regulation: Asking for a Trend
- Josh Lipton takes a closer look at the top stories investors need to know after the closing bell on Asking for a Trend. Hims & Hers Health (HIMS) CFO Yemi Okupe breaks down the quarterly results as shares plunge following the report.
- 02/24/2025
|
Hims & Hers: Post Earnings Drop Is Very Welcomed
- Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITDA increased 163% YoY, highlighting long-term growth potential. Management's goal of 10 million subscribers in 5–6 years, with AI integration and Trybe Labs acquisition, presents a bullish opportunity.
- 02/24/2025
|
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/24/2025
|
Markets Mostly Dip Red Late in Regular Trading
- After the closing bell, Zoom shares are -4% and HIMS are trading -17% lower on Q4 earnings results.
- 02/24/2025
|
Hims & Hers Health, Inc. (HIMS) Lags Q4 Earnings Estimates
- Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.01 per share a year ago.
- 02/24/2025
|
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
- Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales.
- 02/24/2025
|
Hims & Hers shares tumble over concerns around weight-loss business
- The 'Fast Money' traders talk Hims & Hers shares falling despite beat as concerns around weight-loss business escalate.
- 02/24/2025
|
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
- Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage, impacting Hims' weight loss services revenue. Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide. Despite the setback, Hims shows strong financial health with 77% Y/Y revenue growth and no long-term debt, warranting a "hold" recommendation.
- 02/24/2025
|
Overlooked Stock: HIMS
- Hims & Hers Health (HIMS) sold off most of its massive rally today that it got over the last couple weeks. George Tsilis points out that the FDA no longer sees shortages of Novo Nordisk's (NVO) Ozempic and Wegovy weight loss drugs.
- 02/21/2025
|
Why Hims & Hers Health Stock Is Plummeting Today
- Shares of Hims & Hers Health (HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m.
- 02/21/2025
|
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
- The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
- 02/21/2025
|
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
- The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
- 02/21/2025
|
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
- “The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
- 02/21/2025
|
Hims and Hers Stock Drops Weight as Earnings Loom
- Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week.
- 02/21/2025
|
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
- HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. The post Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage appeared first on Investor's Business Daily.
- 02/21/2025
|
HIMS stock crashes 25% on Friday after this key FDA update
- Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01. The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk's weight-loss drugs.
- 02/21/2025
|
Hims & Hers Acquires US-based Peptide Facility
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment.
- 02/21/2025
|
Hims & Hers Health: The Ultimate Pick For The Next Decade
- Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. I provide multiple perspectives in this article, offering readers different viewpoints to draw their own conclusions. There are historical references, future valuations, and timeless investing lessons. There are five primary growth drivers that should continue to turbocharge HIMS' future revenue. I cover them all in detail.
- 02/20/2025
|
Why Hims & Hers Stock Dropped Today
- Hims & Hers Health (HIMS -4.55%) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning.
- 02/20/2025
|
Hims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzz
- Amid a month of skyrocketing stock prices and unprecedented social media buzz, Hims & Hers Health is expanding its territory into at-home blood testing and diagnostics.
- 02/20/2025
|
Atlanta Fed's Bostic, tariffs, Hims & Hers: Market Domination
- Julie Hyman and Seana Smith are joined by key experts as take a closer look at the trending stories on Wall Street on Market Domination. Federal Reserve Bank of Atlanta president Raphael Bostic sits down with Yahoo Finance Senior Fed Reporter Jennifer Schonberger to discuss how the central bank is navigating its recent pause on interest rate hikes amid uncertainty around fiscal policy.
- 02/19/2025
|
Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition
- Hims & Hers Health (HIMS) shares jumped roughly 20% to a fresh record high on Wednesday following the announcement that the company acquired lab testing facility Trybe Labs.
- 02/19/2025
|
Why Hims & Hers Health Stock Is Skyrocketing Today
- Shares of Hims & Hers Health Inc (HIMS 20.27%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m.
- 02/19/2025
|
Hims & Hers to offer at-home blood draws and lab testing with new acquisition
- Hims and Hers Health has acquired at-home lab testing facility Trybe Labs. The acquisition will allow the telehealth company to provide at-home lab testing through its platform.
- 02/19/2025
|
Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making. The company has acquired an at-home lab testing facil.
- 02/19/2025
|
Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
- Hims & Hers Health stock has surged 212% since my previous “buy” rating. Despite strong revenue and earnings growth expectations, I recommend holding off at the moment. Hims & Hers has consistently beat its revenue and earnings for the past several quarters, while the management has raised their forward expectations as a result of their Personalized solutions. However, the latest surge in the stock price is attributed to its provocative Super Bowl ad and favorable outlook on the regulatory landscape after RFK Jr.'s appointment as the Health Secretary.
- 02/18/2025
|
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- There are a few stocks that come along every once in a while, arriving to change the way an old-fashioned industry works and operates. When investors get lucky enough to find one of them, it can typically bring on life-changing returns, even retiring them from active work if they choose to go that route.
- 02/18/2025
|
3 Hot Stocks That Have Already Doubled in 2025
- We're just a few weeks into 2025, but some stocks are already off to the races. There are already nine U.S. exchange-listed stocks with market caps north of $1 billion that have doubled this year.
- 02/18/2025
|
Hims & Hers Stock Is On Fire, But Is It a Bubble?
- Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.
- 02/18/2025
|
What Is Driving Hims & Hers Stock Higher?
- In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.85%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
- 02/18/2025
|
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
- HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
- 02/18/2025
|
Hims & Hers: From Viral Ad to Volatile Stock
- Hims & Hers Health's NYSE: HIMS share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers Health's stock price has attracted considerable attention from investors.
- 02/18/2025
|
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
- Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone.
- 02/18/2025
|
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
- Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
- 02/14/2025
|
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 02/14/2025
|
Buy, Sell, Or Hold HIMS Stock At $60?
- The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widely discussed Super Bowl commercial, which aired on Sunday.
- 02/14/2025
|
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
- Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/14/2025
|
3 Weight-Loss Drug Stocks to Watch
- Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO) , and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most recognized names in the industry.
- 02/13/2025
|
Why Hims & Hers Terrifies Big Pharma
- Hims & Hers (HIMS 1.82%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.
- 02/12/2025
|
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
- The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are permitted when drugs are listed on the FDA's list of drug shortages.
- 02/12/2025
|
Hims & Hers Health: Explosive Growth Potential Ahead
- Hims & Hers has shown significant growth, with a 350% stock gain in 2024, driven by subscriber and revenue increases, and positive free cash flow. The company boasts a strong balance sheet with $250M in cash, no debt, and strategic share repurchases, enhancing shareholder value. Future growth is expected from personalized solutions, with the potential to expand the subscriber base by millions and grow revenue per subscriber.
- 02/11/2025
|
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
- Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment.
- 02/10/2025
|
Herb Greenberg lays out the risks in Apple, Decker and Hims & Hers
- Herb Greenberg, Herb Greenberg on the Street editor, joins 'Power Lunch' to discuss Apple's troubles in China, Deckers headwinds ahead and Hims and Hers core business slump.
- 02/10/2025
|
Hims & Hers Super Bowl ad sparks controversy over weight loss drug sourcing
- CNBC's Brandon Gomez breaks down the controversy around the Hims & Hers Super Bowl ad.
- 02/10/2025
|
Hims & Hers Super Bowl ad draws scrutiny from lawmakers
- Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
- 02/10/2025
|
Hims & Hers Super Bowl ad sparks controversy
- CNBC's Brandon Gomez joins 'Squawk on the Street' to break down the controversy around Hims & Hers Super Bowl ads.
- 02/10/2025
|
Hims & Hers Health: Meme Potential Could Propel Explosive Growth
- Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Putting aside Hims meme potential, the company is still in a great position to disrupt the healthcare industry given its unique platform and business model. While Hims is building an increasingly innovative and high-quality business model, the company still faces major regulatory and competitive hurdles.
- 02/10/2025
|
Hims & Hers stock price target according to the C&H pattern
- Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has soared by almost 1,500% from its lowest level in 2023, transforming it into a leading juggernaut with a market cap of over $9.3 billion.
- 02/10/2025
|
Hims & Hers faces backlash over ‘misleading' Super Bowl ad—but it didn't stop stock from jumping over 11%
- Telehealth company Hims & Hers Health is fighting back after the drug industry's main lobbying group called out its first Super Bowl ad as “misleading” and in potential violation of marketing rules.
- 02/09/2025
|
Global Healthy Living Foundation Says Hims & Hers Health Super Bowl Ad Omits Risks of Weight Loss Drug
- UPPER NYACK, N.Y.--(BUSINESS WIRE)--Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss drug.
- 02/08/2025
|
Hims & Hers faces scrutiny from lawmakers over 'misleading' Super Bowl ad
- Hims & Hers is under fire over an ad for its weight loss offerings that's slated to run during the Super Bowl on Sunday. Two U.S. senators expressed concern over an "upcoming advertisement" that "risks misleading patients by omitting any safety or side effect information.
- 02/07/2025
|
Why Hims & Hers Health (HIMS), Tempus AI (TEM) and Teladoc (TDOC) Are Up Big Today
- Stock markets got a bit of a shock on Friday after a University of Michigan survey showed consumers are anticipating inflation to rise in 2025, potentially depressing consumer spending and dissuading the Fed from making any further cuts to interest rates.
- 02/07/2025
|
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
- The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $42.20, representing a +0.84% change from its previous close.
- 02/05/2025
|
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
- Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.
- 02/05/2025
|
Hims & Hers Launches Health Collective and Community Member Council
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced two new programs dedicated to serving its customers in even more personalized ways, encouraging customers to play an active role in the decisions and choices that shape their healthcare experience. The two groups, the Hims & Hers Health Collective, and the Hims & Hers Community Member Council, are born from the company's mission to help.
- 02/04/2025
|
Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2024 financial results after the market closes on Monday, February 24, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa.
- 02/03/2025
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 02/03/2025
|
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
- HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
- 01/30/2025
|
Hims & Hers Health, Inc. (HIMS) Increases Despite Market Slip: Here's What You Need to Know
- Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.
- 01/29/2025
|
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
- I anticipate the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth rate due to compounding restrictions. I foresee explosive revenue growth post-FDA announcement due to 60-day timelines for pharmacies (503A) and 90-day timelines for outsourcing facilities (503B) to comply with the restrictions. I believe HIMS may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings, creating uncertainty for speculators betting against the stock.
- 01/29/2025
|
Is Hims & Hers Health Stock a Buy?
- Established in 2017, Hims & Hers Health (HIMS -1.17%) is a relatively young company addressing age-old healthcare challenges by offering prescription medications, over-the-counter products, and personal care solutions through a convenient direct-to-consumer model. Since going public via a special purpose acquisition company (SPAC) merger in 2021, the telehealth company and its stock have experienced dramatic transformations.
- 01/28/2025
|
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
- Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.
- 01/22/2025
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 01/21/2025
|
Hims & Hers: Ready To Outperform Further
- Hims & Hers Health is a rapidly growing telehealth leader with a unique, customer-focused business model, demonstrated by its aggressive customer base expansion and accelerating revenue growth momentum. The company's strong operating leverage, consistent EBITDA margin expansion, and robust free cash flow have built a fortress balance sheet, enabling both organic and inorganic growth opportunities. My intrinsic value per share estimate is significantly higher compared to the current share price.
- 01/20/2025
|
Hims & Hers Health: A Stock to Trade or Own?
- Hims & Hers Health Inc. NYSE: HIMS, a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024, significantly outperforming the broader market and its sector.
- 01/20/2025
|
Hims & Hers Health: The Market Is Likely Wrong
- Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90% YoY Q4 growth and strong non-GLP-1 business expansion. Hims' innovative product launches, such as meal replacement bars, highlight its focus on personalized health services and continuous growth potential.
- 01/19/2025
|
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
- A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m.
- 01/17/2025
|
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
- 01/17/2025
|
Is Hims & Hers Stock in Trouble?
- Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks to own in healthcare of late.
- 01/16/2025
|
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
- Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $25.90, moving +1.93% from the previous trading session.
- 01/13/2025
|
Hims & Hers Stock Is Poised for a Major Surge in 2025
- Hims & Hers (HIMS -4.02%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Travis Hoium explains why investors should expect an expanded platform in 2025.
- 01/10/2025
|
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
- Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Forecasting $3.79B in revenue and $1.08 EPS by 2030, a $45.90 midpoint price target implies an 11.5% five-year CAGR, underperforming a 15% return expectation for a Buy rating. Despite strong branding and subscription revenue, slim competitive advantages and valuation concerns justify a Hold rating, emphasizing risks from generic pricing and market competition.
- 01/09/2025
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 01/08/2025
|
Hims & Hers donates $1 million to Trump's inauguration fund
- Hims & Hers Health has donated $1 million to President-elect Donald Trump's inauguration fund, CNBC confirmed Tuesday. The company is the latest in a string of tech organizations that have tried to curry favor with the incoming administration.
- 01/07/2025
|
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
- Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $26.90, moving +1.01% from the previous trading session.
- 01/06/2025
|
Hims & Hers: Ready For Liftoff In 2025
- Despite a recent 30% stock drawdown, Hims & Hers Health, Inc. remains a “Strong Buy” due to its undervaluation and long-term growth potential in the healthcare tech market. Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its strong growth trajectory. Management's raised FY-2024 revenue outlook and strategic initiatives, including new weight loss offerings and personalization, bolster confidence in sustained growth.
- 01/02/2025
|
Is Hims & Hers Health a Millionaire Maker?
- Hot telehealth stock Hims & Hers Health (HIMS -3.93%) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high.
- 01/01/2025
|
3 Hot Stocks That Can Double Again in 2025
- Some of the hottest stocks of 2024 may surprise you. A few more than 100 stocks with market caps north of $2 billion doubled over the past year.
- 12/31/2024
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 12/27/2024
|
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
- Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
- 12/23/2024
|
Hims & Hers: Still Trading At A Massive Discount
- Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and differentiation. HIMS' financials are robust, with 40% annual subscription growth and a forecasted 60%+ revenue growth for 2024, indicating significant undervaluation despite a 200% YTD increase. The company is expanding its product offerings and leveraging AI through MedMatch, enhancing treatment consistency and customer satisfaction, further solidifying its market position.
- 12/23/2024
|
Will the falling Hims & Hers stock price recover in 2025?
- Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS Health and Walgreens Boots Alliance and CVS Health, plunged.
- 12/22/2024
|
Hims & Hers Stock: Growth, Noise, and Where to Focus Now
- Hims & Hers Health (HIMS -7.67%) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this video.
- 12/20/2024
|
Hims and Hers Health Stock Testing Key Trendline
- Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15.
- 12/19/2024
|
CEO of HIMS dumps over $6 million of stock
- Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven't exactly been performing well as of late.
- 12/18/2024
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 12/16/2024
|
HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?
- Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly outperforming the industry's growth of 5.5%.
- 12/16/2024
|
The Shape of America 2024: Hims & Hers Shares an In-Depth Look Into How Americans Feel About Weight
- SAN FRANCISCO--(BUSINESS WIRE)--For most Americans, weight is more than just a number. It shapes our health, our mood, our confidence, our spending, and the decisions we make in our day to day lives. In fact, 75% of us think about our weight every single day, and 14% say it's constantly on our minds. At Hims & Hers (NYSE: HIMS), we know that health is personal, which is why we focus on making high-quality, affordable personalized health and wellness solutions to our customers. Along with pr.
- 12/12/2024
|
Hims & Hers: Look At What Matters Most
- Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS companies in terms of scalability and growth potential. The company reported stellar Q3 FY2024 results with a 77% YoY revenue increase, driven by strong subscriber growth and high retention rates in personal health services. Despite regulatory risks and competition, HIMS' advanced tech platform and focus on personalized healthcare provide a strong foundation for long-term shareholder value.
- 12/12/2024
|
4 Stocks That Crushed Analyst Estimates by More Than Double
- Every earnings season has its share of winners and losers, as well as top and bottom-line surprises and disappointments. This recent earnings season is no different.
- 12/11/2024
|
Options Action: Bearish bets on Hims
- Mike Khouw joins 'Fast Money' to talk the options trade around Hims.
- 12/10/2024
|
Market Navigator: Hims & Hers Health up 250% in 2024
- Todd Gordon, founder of Inside Edge Capital, joins CNBC's 'Power Lunch' to discuss why he's keeping an eye on shares of these healthcare picks, potential headwinds, and more.
- 12/10/2024
|
Hims & Hers: The Show Must Go On
- Hims & Hers Health stock is substantially undervalued despite a massive YTD rally, presenting a strong buy opportunity due to a myriad of catalysts. The company demonstrates exponential revenue growth, improving operating margins, and successful customer acquisition cost reduction, driven by personalized solutions and innovative product formats. HIMS is financially strong with minimal debt and a dominant market share, strategically positioned to leverage AI-driven tools and proprietary systems for growth.
- 12/05/2024
|
Stock Picks From Seeking Alpha's November 2024 New Analysts
- Twenty-six new analysts joined Seeking Alpha in November, sharing diverse investment ideas highlighting their unique backgrounds and expertise. Top picks include U.S. Bancorp Preferred Series A, Hershey, and PepsiCo, emphasizing undervalued opportunities, dividend stability, and strategic growth potential. Analysts also spotlighted strong sell recommendations like BlackRock Science and Technology Trust and Luckin Coffee, citing fundamental flaws and competitive disadvantages.
- 12/05/2024
|
2 Telehealth Stocks That Could Gain from Trump's New FDA Pick
- The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform.
- 12/05/2024
|
Hims & Hers Vs. Amazon: Why David Defeats Goliath
- Hims & Hers has shown significant growth in the telehealth market, facing competition mainly from Amazon, but has unique advantages. HIMS's agility, focused resource allocation, and strong market fit give it an edge over Amazon's less dedicated telehealth efforts. Valuation suggests a target price of $37, with potential for a +15% upside, but caution is advised around the $40 mark.
- 12/05/2024
|
Hims & Hers Named to Inc.'s 2024 Best in Business List in Health Products Category
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, is proud to announce its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. Inc.'s Best in Business list recognizes companies that, through except.
- 12/03/2024
|
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 12/03/2024
|
Hims & Hers: Driving Growth In Wellness
- Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Q3 2024 revenue rose 77% YoY to $401.6M, with $392.6M from online channels (+79% YoY). GLP-1 patient retention at 12 weeks reached 70%, outperforming the industry average of less than 42%.
- 11/29/2024
|
Why Hims & Hers Stock Jumped on Massive FDA News
- Shares of Hims & Hers (HIMS 0.67%) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a business similar to Hims & Hers. In this video, Travis Hoium covers why this is important and why the stock is moving as fast as it is.
- 11/26/2024
|
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
- Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
- 11/25/2024
|
Him & Hers Health Stock Doubled Options Bulls' Money
- Schaeffer's Weekend Trader subscribers scored a big win just in time for Thanksgiving.
- 11/25/2024
|
Bulls: Bet on a Rebound for This Telehealth Stock
- Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters.
- 11/22/2024
|
Hims & Hers New Growth Category Is a Huge Surprise
- Is the food business the right business for Hims & Hers to be in?
- 11/22/2024
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 11/22/2024
|
What's Happening With HIMS Stock?
- The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of Eli Lilly's weight loss drug – Zepbound.
- 11/22/2024
|
The FDA Can't Decide Whether Zepbound Is in Shortage. It's Good News for Hims & Hers Stock.
- Hims & Hers markets a compounded version of a similar medicine sold by Novo Nordisk.
- 11/21/2024
|
Hims & Hers Expands Nutrition Support to Fuel Customers' Weight Loss Journeys
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that Hims & Hers customers will now be able to supplement their treatment plan with daily meal replacement bars and shakes to support them on their comprehensive weight loss journey. Hims & Hers is elevating its offering to supplement the comprehensive, individualized weight management plans, designed by doctors, that take every aspect o.
- 11/21/2024
|
Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead
- Hims & Hers Health can potentially face significant competition from Amazon's aggressive pricing and broad telehealth offerings, but its personalized care and strong financials offer resilience. Not every market Amazon has stepped into has been super disruptive, even if the market initially thought it would be. One example I mention is Amazon's Whole Foods acquisition. Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and no debt.
- 11/20/2024
|
Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confiden.
- 11/18/2024
|
Hims & Hers Stock Is Down 30% This Week: Here's What Happened
- Hims & Hers has given back recent gains, but don't overlook the company's massive growth.
- 11/16/2024
|
Should You Buy Hims & Hers Stock on the Dip?
- Should You Buy Hims & Hers Stock on the Dip?
- 11/16/2024
|
Hims & Hers: Revolutionizing Telehealth And Captivating Investors - Here's Why You Should Buy
- Hims & Hers stands out from Teladoc by focusing on direct-to-consumer telehealth services, contrasting Teladoc's business-to-business model. This telehealth company provides personalized treatments to select conditions like weight loss, hair loss, and sexual health. A reverse DCF analysis suggests its current stock price is more than justified.
- 11/16/2024
|
Hims & Hers Health: The Amazon Curse Is Being Overstated
- Hims & Hers Health, Inc.'s stock dropped over 25% over the last 2 days due to Amazon's entry into the hair loss and ED markets, but I believe investor pessimism is overblown. Despite Amazon's competition, Hims & Hers's focus on personalized solutions, which saw 175% YoY growth, provides a strong competitive moat. Even with conservative growth estimates, Hims & Hers has a 38% upside potential, maintaining my “buy” rating with a $27.5 price target.
- 11/15/2024
|
Hims & Hers stock tanks as Amazon debuts fixed pricing for hair-loss and erectile-dysfunction drugs
- Hims & Hers Health, a telehealth service for clients to access healthcare and prescriptions from home, is seeing its stock take a steep dive on Thursday, just after Amazon announced updates to a strikingly similar service for Prime members.
- 11/15/2024
|
Hims & Hers' stock tumbles on Amazon's latest disruptive foray into healthcare
- Amazon is now offering upfront pricing for virtual care for ailments such as men's hair loss and ED.
- 11/14/2024
|
Amazon's push into telehealth knocks shares of Hims & Hers
- Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing for telehealth visits.
- 11/14/2024
|
Amazon launches fixed pricing to treat conditions like hair loss. Hims & Hers stock drops 15%
- Amazon announced Prime members can access new upfront pricing to treat five common conditions like erectile dysfunction and men's hair loss. The move places the company in competition with other direct-to-consumer marketplaces like Hims & Hers Health and Ro.
- 11/14/2024
|
Telehealth firm Hims & Hers launches weight-loss drug shortage tracker
- Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's Wegovy.
- 11/13/2024
|
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
- HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
- 11/13/2024
|
SHOP, CVNA, HIMS Highlight Strength & Diversity in Consumer Discretionary
- Shopify's (SHOP) massive pop after earnings is just the latest flex of Consumer Discretionary's strength, according to Roxanna Islam. The sector has grown 20% year-to-date compared to Consumer Staples.
- 11/12/2024
|
Up 298% in a Year, Is Hims & Hers Health Still a Buy?
- The healthcare company is on fire, and it's still cheap by many measures.
- 11/12/2024
|
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance
- Every earnings season has its share of outperformers, companies that report blowout quarters and raise their forecasts. The market reacts quickly sending shares sharply higher.
- 11/12/2024
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 11/11/2024
|
Hims & Hers: Undeservedly Undervalued
- H&H's strong Q3 results signals a fundamental shift in the healthcare industry. GLP-1 drugs are certainly a growth catalyst for H&H but it is just a tiny component of the overall investment thesis. H&H investments in AI will drive massive efficiency gains while delivering immense value for providers and patients.
- 11/09/2024
|
Hims & Hers: A High-Growth Gem On The Verge Of Big Upside
- Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported a 77% year-over-year revenue growth, with a subscriber base of 2 million. Hims & Hers' strategic marketing investments have led to positive net income, with potential for further growth and profitability.
- 11/08/2024
|
Earnings Estimates Moving Higher for Hims & Hers Health (HIMS): Time to Buy?
- Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 11/08/2024
|
After Another Blowout Quarter of Surging Revenue, Is Hims & Hers Stock a Once-in-a-Decade Buy?
- Hims & Hers strong performance involves much more than just GLP-1 drugs.
- 11/08/2024
|
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
- The company expects to enjoy many GLP-1 tailwinds in 2025.
- 11/06/2024
|
Hims & Hers: Why This Healthcare Stock's Growth Makes It a Buy
- Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thinking that it is now too late to get into action. This might be the case for shares of Hims & Hers Health Inc. NYSE: HIMS, as the stock is now rallying by over 6% the morning after the company reported its quarterly earnings.
- 11/06/2024
|
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
- Hims & Hers Health (HIMS) reported third-quarter results that topped analysts' expectations Monday, lifting its shares, as the company said t plans to release a generic version of a Novo Nordisk (NVO) diabetes and weight-loss drug as early as next year.
- 11/05/2024
|
Hims & Hers Health CFO talks GLP-1s, earnings
- Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, helped by a tax benefit and strong demand for GLP-1 weight-loss drugs.
- 11/05/2024
|
Hims & Hers Health: Another Blowout Quarter Ignored
- Hims & Hers Health, Inc. reported record Q3 '24 revenues of over $400 million, beating estimates by nearly $19 million, and guided for up to 90% growth in Q4. The online health and wellness platform saw a 44% YoY subscriber growth, reaching 2 million subscribers, led by 175% growth in personalized services. Despite booming sales and strong financials, the stock remains undervalued, trading below 3x 2025 sales targets and only 22x updated adjusted EBITDA.
- 11/05/2024
|
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
- Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
- 11/05/2024
|
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
- The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.
- 11/05/2024
|
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
- Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading after the strong Q3 results and raised outlook (~8 points higher on growth and 2 points of additional adjusted EBITDA margin). HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to direct-to-consumer models.
- 11/04/2024
|
Hims & Hers Health, Inc. (HIMS) Q3 2024 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder and CEO Yemi Okupe - CFO Patrick Carroll - Chief Medical Officer Conference Call Participants Allen Lutz - Bank of America Maria Ripps - Canaccord Daniel Grosslight - Citi Eric Percher - Nephron Research Ryan MacDonald - Needham Aaron Kessler - Seaport Research Jonna Kim - TD Cowen Jailendra Singh - Truist Securities Operator Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today.
- 11/04/2024
|
Markets Temper Enthusiasm Ahead of Election Day
- We don't expect any sudden movements in the stock market until Wednesday morning the earliest.
- 11/04/2024
|
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
- Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
- 11/04/2024
|
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'
- Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-loss drugs continue to draw subscribers.
- 11/04/2024
|
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
- Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
- 11/04/2024
|
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
- The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
- 11/01/2024
|
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
- Disrupting pharmacies is just the start for Hims & Hers.
- 10/30/2024
|
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 10/29/2024
|
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
- Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2024
|
Top 3 Stocks Institutions Are Buying Right Now
- Despite the S&P 500 trading near its all-time high today, some stocks still offer a potential buy opportunity for investors to consider, especially after some institutions have come along to buy and increase some of their positions in these stocks today to reiterate their long bias and optimism in these companies moving forward.
- 10/28/2024
|
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
- In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $21.52, marking a +0.65% move from the previous day.
- 10/24/2024
|
Hims & Hers Stock Dropped: Here's What You Need to Know
- The GLP-1 drama continues at Hims & Hers.
- 10/24/2024
|
Hims & Hers Health Tops Growth 50 List As FDA OKs Cheaper Weight-Loss Drug
- Hims stock is near its all time high and a buy point of 25.74.
- 10/21/2024
|
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced Dr. Jessica Shepherd is joining as the first Chief Medical Officer of Hers. As the company invests further in personalized healthcare designed for women, Dr. Shepherd will guide the clinical expertise that forms the foundation of the Hers brand across sexual health, dermatology, weight loss, and mental health. Dr. Shepherd brings nearly twenty y.
- 10/21/2024
|
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
- Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 10/18/2024
|
Why Hims & Hers' Incredible Growth Will Continue
- GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.
- 10/18/2024
|
HIMS: GLP-1 Is Just The Beginning
- Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue growth and 270% EBITDA increase, signaling strong financial health and future potential.
- 10/17/2024
|
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
- Hims & Hers Health (HIMS) shares surged Monday after the Food and Drug Administration (FDA) said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage of their active ingredient.
- 10/14/2024
|
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter financial results after the market closes on Monday, November 4, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenci.
- 10/14/2024
|
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
- Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
- 10/14/2024
|
FDA Buzz Sends Health and Wellness Stock Surging
- Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA).
- 10/14/2024
|
Where Does Hims & Hers Stock Go From Here?
- Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
- 10/12/2024
|
2 Incredibly Cheap Growth Stocks to Buy Right Now
- Look beyond the stock price at the business when shares are volatile.
- 10/12/2024
|
2 No-Brainer Growth Stocks to Buy With $500 Right Now
- Consistently investing even moderate sums can grow your portfolio with time.
- 10/12/2024
|
What Is Going On With Hims & Hers Stock?
- Big GLP-1 news could have an impact.
- 10/11/2024
|
Top 3 Stocks with Explosive Call Option Activity: What to Watch
- When considering a long position in a stock, investors usually consider buying shares in a company to express their views. However, they need to realize that there is a much more aggressive way to gain long exposure to a stock.
- 10/10/2024
|
Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?
- Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/08/2024
|
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
- The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S&P 500 index. However, there is still a preference for the technology sector, and this preference is now being diversified away from the semiconductor industry and into other niches.
- 10/08/2024
|
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 10/07/2024
|
Hims & Hers Health Set to Join S&P SmallCap 600
- NEW YORK , Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions.
- 10/04/2024
|
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
- Thursday, The FDA determined the shortage of Eli Lilly And Co's LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
- 10/04/2024
|
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over
- Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly's obesity and diabetes drugs are no longer facing supply constraints, and have been removed from the shortage list.
- 10/04/2024
|
Massive News for Hims & Hers Stock: The Truth About Today's Move
- Hims & Hers may not be hurt by GLP-1 news the way investors think.
- 10/04/2024
|
2 Winning Growth Stocks That Are Screaming Buys Right Now
- These top stocks are on a winning streak and have the businesses to keep it going.
- 10/04/2024
|
Market Today: Oil Prices Surge Amid Middle East Tensions, Hims & Hers Dips
- The S&P 500 closed just below 5,700, dropping nearly ten points or 0.2% from the previous day. Meanwhile, the Nasdaq Composite remained relatively flat, the Dow Jones Industrial Average fell by 0.4%, and the Russell 2000 declined by 0.7%.
- 10/03/2024
|
3-Stock Lunch: Nvidia, Levi Strauss & Co & Hims & Hers Health Inc
- Quint Tatro, Joule FInancial president, joins 'Power Lunch' to discuss stock plays for three stocks.
- 10/03/2024
|
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
- Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly's (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its list of drugs in short supply.
- 10/03/2024
|
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
- Hims & Hers stock is undervalued at 25x forward free cash flow, presenting a tremendous bargain given its strong fundamentals and growth potential. Despite volatility and marketing spend concerns, Hims & Hers boasts over 2 million paying subscribers, with significant growth expected organically, not just from GLP1 products. With no debt and over $230 million in cash, Hims & Hers is financially robust and profitable, projecting $220 million EBITDA and $170 million free cash flow in 2025.
- 10/03/2024
|
Is the soaring Hims & Hers stock a good investment?
- Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in the last 12 months and by 112% this year, outperforming the benchmark Nasdaq 100 and S&P 500 indices and other companies in the healthcare industry.
- 10/03/2024
|
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
- Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
- 10/02/2024
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 09/25/2024
|
Hims & Hers: The Gift That Keeps On Giving
- Hims & Hers stock is currently in the middle of a deep drawdown, with HIMS stock nearly 35% off of its recent highs. However, the telehealth platform company remains a fundamentally sound business and is getting stronger by broadening its diversified weight loss offering through the addition of compounded GLP-1s. As of Q2, Hims & Hers is delivering top-line hypergrowth, and turning into an FCF machine.
- 09/25/2024
|
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
- Hims & Hers is a fantastic value despite its high 'on-the-surface' P/E ratio and valuation metrics. The company's subscription-based model in healthcare, targeting chronic conditions, ensures recurring revenue and high customer retention, leading to consistent revenue growth. High gross margins lead to incredible operating leverage, and we see net income increasing from $15 million to more than $600 million in the next 24 months.
- 09/24/2024
|
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts
- The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.
- 09/23/2024
|
Where to put $1,000 in stocks to make $10k in 2025
- While it is no secret that assets in the stock market can offer substantial profits to skillful investors and traders, it is sometimes difficult to discern which stocks are better than others in this regard and which could provide an income of, say, $10,000 from investing a mere $1,000 in them.
- 09/23/2024
|
Hims & Hers offers compounded Wegovy for $99 a month to select professions
- U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.
- 09/18/2024
|
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare, today announced access to the most common compounded GLP-1 subscriptions for as low as $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have.
- 09/18/2024
|
Hims & Hers Acquisition: How Innovation Will Flourish
- Buying a new pharmacy will allow Hims & Hers to expand into new markets.
- 09/18/2024
|
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
- This telemedicine company seems to leapfrog from one hot area in healthcare to another. Its strategy of acquiring members and turning them into paid subscribers is promising.
- 09/17/2024
|
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
- Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.
- 09/16/2024
|
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
- Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
- 09/16/2024
|
Hims & Hers Stock Pops After Massive Acquisition
- Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
- 09/13/2024
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 09/13/2024
|
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
- Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
- 09/11/2024
|
Is Hims & Hers Health the Next Teladoc?
- Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
- 09/11/2024
|
Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long
- Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.
- 09/10/2024
|
Is Hims & Hers Health Stock a Buy?
- Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.
- 09/10/2024
|
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
- HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
- 09/05/2024
|
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
- Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
- 09/05/2024
|
The Big 3: HIMS, TLT & WFC
- Ben Lichtenstein and Don Kaufman focus on finance and health in today's Big 3. They break down the technical trends for Hims & Hers (HIMS), the iShares 20+ Year Treasury Bond (TLT), and Wells Fargo (WFC).
- 09/04/2024
|
Has Eli Lilly Destroyed Hims & Hers Upside?
- Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
- 09/03/2024
|
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 09/02/2024
|
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
- Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
- 09/01/2024
|
2 No-Brainer Growth Stocks to Buy With $200 Right Now
- Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
- 08/31/2024
|
Why Hims & Hers Health Stock Was Falling This Week
- Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.
- 08/29/2024
|
Is Hims & Hers Health Stock a Buy?
- Hims & Hers has carved a strong niche in the men's healthcare segment while expanding into other areas. The weight-loss category is a huge opportunity for the company.
- 08/29/2024
|
Why Hims & Hers Stock Crashed on Tuesday
- Eli Lilly's Zepbound got a 50% price cut that could take some of Hims & Hers growth potential. Lower-cost drugs could be good news for Hims & Hers long term.
- 08/27/2024
|
Hims & Hers Health Stock Takes Hit as Eli Lilly Offers Cheaper Weight-Loss Drug
- Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
- 08/27/2024
|
Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.
- The new option is priced at a 50% or more discount compared to other weight-loss drugs.
- 08/27/2024
|
What Is Going On With Hims & Hers Stock?
- After a strong start to the year, the stock is down 30% since June.
- 08/22/2024
|
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
- Hims & Hers Health stock is up over 37% since my initial coverage, as the company is experiencing strong investor optimism from its compounded GLP-1 additions to its Weight Loss portfolio. The company reported its Q2 FY24 earnings where revenue and Adjusted EBITDA grew 52% and 270% YoY respectively, as subscribers opting for Personalized Solutions grew over 164% YoY. While Hims generated close to $15M in Q2 from GLP-1 medications, it is simultaneously innovating and expanding its personalized solutions across its tenured and new specialties.
- 08/20/2024
|
Hims & Hers Health: Healthy Gift
- Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sales targets to over $375 million. The stock would trade at $41 based on trading at just 5x EV/S targets.
- 08/20/2024
|
Hims & Hers: Great Value Amid Unwarranted Concerns (Rating Upgrade)
- Hims & Hers stock has dropped ~30% from recent peaks despite raising its outlook for FY24. Investors are concerned over projections for the company's weight loss compound drugs, especially if the FDA-approved Wegovy and Ozempic see better supply. Still, the company's weight loss revenue is only contributing a small fraction of its outstanding growth rates today, built across a wide range of specialties.
- 08/20/2024
|
Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
- Subscriber growth reaccelerated, focus on personalized products, over 40% subscribers use personalized solutions. Stock-based compensation concern, $100M buyback program, increased marketing spend, positive outlook for Hims' future. GLP-1 offering still in a gray area, path forward looks difficult but possible.
- 08/20/2024
|
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
- Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 08/20/2024
|
2 Magnificent Stocks That Are Screaming Buys in August
- While the stock market has been volatile lately, quality businesses are still performing. Hims & Hers Health is profitable and rapidly expanding its subscriber base.
- 08/19/2024
|
Is Hims & Hers Health the Best Growth Stock for You?
- Hims & Hers stock is trading based on speculation about its success with weight loss drugs. But that's a very small part of its business.
- 08/16/2024
|
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
- Novo Nordisk and Eli Lilly are currently the major players in the weight loss market. Hims & Hers Health is looking to disrupt the space by offering a lower-cost alternative.
- 08/16/2024
|
Top 3 Stocks to Watch: Options Traders Bet on Big Gains
- Investors had to deal with the sudden volatility in the stock market last week after the S&P 500 erased trillions in wealth. Not to mention the additional losses suffered by the Nikkei 225 (Japan's version of an S&P 500), arguably initiating the downtrend altogether.
- 08/13/2024
|
Hims & Hers Health Boosts Outlook. Is This a Golden Opportunity to Buy the Stock?
- Hims & Hers' revenue and profit metrics soared in the second quarter. Growth is expected to accelerate in the second half following the launch of the company's GLP-1 offering.
- 08/11/2024
|
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
- Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 08/09/2024
|
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
- Hims just reported record Revenue, Profits, and Cash Flows, signifying improving fundamentals. This was driven by robust growth in its core offerings as well as the launch of its new Weight Loss offering. Demand for Hims products is so strong that management raised Revenue guidance by more than $100M.
- 08/07/2024
|
Hims & Hers Stock Crashed but This Is a Growth Machine
- Don't overlook the 52% growth in the second quarter.
- 08/07/2024
|
Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Most investors have had to worry about the accelerating sell-offs happening across the global stock markets this week, which aren't being encouraged by news from Warren Buffett's latest decisions. The Oracle decided to start decreasing its exposure to some of America's technology darlings, such as Apple Inc. NASDAQ: AAPL, which was cut by 50%, or Bank of America Co. NYSE: BAC.
- 08/06/2024
|
Hims & Hers Health, Inc. (HIMS) Q2 2024 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder & CEO Yemi Okupe - CFO Conference Call Participants Maria Ripps - Canaccord Allen Lutz - Bank of America Jack Wallace - Guggenheim Securities Daniel Grosslight - Citi Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Glen Santangelo - Jefferies George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2024 Earnings Conference Call.
- 08/05/2024
|
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
- Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.
- 08/05/2024
|
Shares of Hims & Hers, known for hair-loss treatments and Viagra, rally amid market panic
- Shoppers might be spending less or seeking cheaper deals on takeout food and household items, and investors on Monday were panicking about the U.S. economy. But Hims & Hers Health Inc. — the online telehealth platform best known for selling hair-loss treatments, Viagra and Cialis — said customers are still piling in.
- 08/05/2024
|
Instant Earnings Reaction: Palantir (PLTR), Hims & Hers (HIMS)
- Palantir (PLTR) jumps on an earnings beat and increased A.I. demand. Kevin Green and Scott Durfey dive into A.I.
- 08/05/2024
|
Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Our second quarter results mark an acceleration in what was already an incredible trajectory. During the quarter, subscribers on our platform approached 1.9 million, increasing 43% year-over-year," said And.
- 08/05/2024
|
3 Telemedicine Stocks Poised for Possible Healthcare Evolution
- Telemedicine stocks could do no wrong during the pandemic. With millions on lockdown and still in need of medical care, telemedicine stocks, like Teledoc Health (NYSE:TDOC) ranfrom about $80 to a high of $288.80.
- 08/05/2024
|
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
- Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
- 08/05/2024
|
Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Recently, weight loss and diabetes watch company DexCom Inc. NASDAQ: DXCM stock plummeted by over 44% on a surprisingly bad quarterly earnings report. Management guided lower – much lower – than analysts had expected to see revenue and earnings per share (EPS), and it all had to do with the decreasing demand for the company's medical devices, which are being replaced more and more by effective medicine lately.
- 08/03/2024
|
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
- Hims & Hers is offering customers access to compounded GLP-1 weight loss drugs. Compounded drugs are only available when there's a shortage.
- 08/02/2024
|
Got $200? 2 Best Growth Stocks to Buy and Hold Forever
- Spending on healthcare and online purchases is rising even as consumer wallets remain constrained. Hims & Hers offers virtual care services and prescriptions through a simple recurring subscription plan.
- 08/01/2024
|
Hims & Hers Health Stock Flashing Buy Signal Before Earnings
- After a late-May bull gap on the charts, healthcare stock Hims & Hers Health Inc (NYSE:HIMS) steadily worked higher to snag a record high of $25.74 on June 18.
- 07/31/2024
|
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
- Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.
- 07/30/2024
|
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
- Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2024
|
Can Hims & Hers Health (HIMS) Run Higher on Rising Earnings Estimates?
- Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 07/26/2024
|
3 Game-Changing Stocks on the Edge of Unprecedented Gains
- Uncovering the best game-changing stocks to buy is a true holy grail for achieving considerable financial returns while investing. Here are three standout companies ready to shift the valuation landscape.
- 07/25/2024
|
Red-Hot Prescription Stock Flashing A Bullish Signal
- Prescription stock Hims & Hers Health (HIMS) is down 2.8% to trade at $22.45 today, and last week suffered a 10.6% drawdown. The upside is that the pullback has HIMS brushing up against a historically bullish trendline, if past is precedent.
- 07/25/2024
|
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
- Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.
- 07/24/2024
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 07/23/2024
|
Hims & Hers Health: Expecting A Healthy Report
- Hims & Hers Health has fallen below $20 after initial excitement over a compounded GLP-1 drug solution wanes. The health and wellness platform offers a compounded semaglutide drug at lower prices due to shortage of name-brand drugs. A short report from Hunterbrook Media questioned the business practices, but the investment story isn't based on the GLP-1 drug compound.
- 07/21/2024
|
Here's My Top Growth Stock to Buy Right Now
- Hims & Hers' unique, brand-driven strategy can help it establish a moat in the competitive telehealth industry. Over the long term, the company can leverage user data and artificial intelligence to generate shareholder value.
- 07/20/2024
|
Is This Telehealth Stock a Buy After the Recent Pullback?
- Hims & Hers Health, Inc. NYSE: HIMS is a prominent player in the telehealth sector, which is part of the larger healthcare sector. The company has garnered significant attention from investors due to its remarkable rise in the stock market.
- 07/19/2024
|
Hims & Hers: The Thesis Goes Far Beyond GLP-1
- Hims & Hers is dedicated to telehealth and provides healthcare services remotely. It has an asset-light business model that has had extraordinary growth. The company began its growth by attacking markets sometimes overlooked by traditional medicine, such as dermatology or mental health. According to my valuation model, the stock could triple if it grows 35% annually in the coming years and reaches EBITDA margins of 25%. In my opinion, it's realistic.
- 07/18/2024
|
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
- In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.11, indicating a +1.18% shift from the previous trading day.
- 07/16/2024
|
Hims & Hers to Announce Second Quarter 2024 Financial Results on August 5, 2024
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday, August 5, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenci.
- 07/15/2024
|
3 Stocks Poised to 10X in the Next 5 Years
- Identifying stocks with the potential to achieve extraordinary returns can be complex and rewarding. Three companies can fundamentally hit solid market value growth over the next five years.
- 07/15/2024
|
2 Incredibly Cheap Growth Stocks to Buy Now
- These companies are on different growth trajectories, but each has something to offer long-term investors. Hims & Hers is increasing subscribers and revenue rapidly, while profitability is expanding.
- 07/14/2024
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 07/12/2024
|
3 Companies Set to Positively Surprise this Earnings Season
- Earnings season has arrived, with Friday's big bank results shifting the period into a much higher gear. The period looks to be positive, with earnings growth expected to be strong, again underpinned by a strong forecasted showing from the Tech sector.
- 07/11/2024
|
2 Top-Ranked Cheap Growth Stocks to Buy in July and Hold
- The two stocks trading under $25 per share we dive into today boast impressive growth outlooks and their improving earnings estimates help them land Zacks Rank #1 (Strong Buys).
- 07/11/2024
|
Hims & Hers' February gains were important in bringing it over the SPAC $10 level, says Jim Cramer
- 'Mad Money' host Jim Cramer takes a look at Hims & Hers to assess if its a good healthcare move for your portfolio.
- 07/10/2024
|
Don't place your hopes on Hims & Hers GLP-1 business, says Jim Cramer
- 'Mad Money' host Jim Cramer takes a look at Hims & Hers to assess if its a good healthcare move for your portfolio.
- 07/10/2024
|
Jim Cramer on Hims & Hers Health stock: 'I bet the business stays strong'
- CNBC's Jim Cramer gave his take on the Hims & Hers Health, a digital health and wellness platform, saying it might be worth opening a position in the stock now that it's pulled back somewhat from its highs. Hims & Hers offers telehealth services and direct-to-consumer treatments for erectile dysfunction and hair loss, and it just announced it would start selling compounded GLP-1 weight loss injections.
- 07/10/2024
|
Are Medical Stocks Lagging Hims & Hers Health (HIMS) This Year?
- Here is how Hims & Hers Health, Inc. (HIMS) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
- 07/08/2024
|
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
- Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
- 07/05/2024
|
3 Stocks That Can Double Again in 2024
- Cava, Hims & Hers Health, and Sweetgreen have more than doubled in 2024. Cava and Sweetgreen should continue to benefit from the return to in-office workplaces.
- 07/02/2024
|
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
- Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new report criticized those offerings, saying that they're being acquired through a “shady supplier.”
- 07/01/2024
|
Is Hims & Hers Stock a Buy After Short Report?
- There are valid points in the short report, but it may present a buying opportunity for long-term investors.
- 06/29/2024
|
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
- Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
- 06/28/2024
|
Hims & Hers shares fall on Hunterbrook report that GLP-1 drugs come from 'shady supplier'
- Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'.
- 06/27/2024
|
Hims & Hers Stock Drops 12.8% After Short Report
- A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock.
- 06/27/2024
|
Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report
- Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes research on stocks through Hunterbrook Media while sometimes taking a position in the same stock through its hedge fund affiliate, Hunterbrook Capital.
- 06/27/2024
|
2 Top Growth Stocks to Buy With $500 Right Now
- Consumer spending on healthcare and restaurants is resilient in a range of economic environments. Hims & Hers is tapping into the potential of the lucrative telehealth market.
- 06/26/2024
|
Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know
- In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.
- 06/24/2024
|
Should You Buy Hims & Hers Health Stock Right Now?
- The telehealth company is offering innovative products at lower prices.
- 06/24/2024
|
5 Medical Info Systems Stock to Buy for a Stable Portfolio
- We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
- 06/24/2024
|
3 Reasons to Buy Hims & Hers Health Stock Now
- Summer has officially begun, but some stocks are receiving a chilly reception today.
- 06/20/2024
|
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 06/19/2024
|
Hims & Hers: The Undervalued Gem Poised For Growth
- As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already started shipping out injections to subscribers. HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.
- 06/18/2024
|
3 Sector Stars Lead Growth: Foot Locker, Shake Shack, Hims & Hers
- One of the market's most closely watched economic reports made a sudden turn last week. The employment situation report (NFP) showed that the U.S. economy is still resiliently adding jobs despite seeing some contradicting indicators placing a ceiling on its growth.
- 06/10/2024
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
- 06/07/2024
|
5 Phenomenal Relative Price Strength Stocks to Snap Up Now
- VITL, HIMS, ANF, CHWY and GPS are five stocks with explosive relative price strength.
- 06/06/2024
|
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
- Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand and generic versions of Pfizer Inc. NYSE: PFE Viagra (Sildenafil) and Eli Lilly & Co. NYSE: LLY Cialis (Tadalafil).
- 06/03/2024
|
Hims & Hers Health Stock Soared This Week: Here's Why
- Hims & Hers recently launched weight loss drugs at a disruptive price point. The company is growing revenue quickly.
- 06/01/2024
|
Call Option Volumes Spiked For These 3 Stocks
- As the saying goes, always follow the money. This time, investors can follow the proverbial big players through an options activity screener, spotting unusual trends in how markets are betting.
- 05/30/2024
|
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
- Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
- 05/28/2024
|
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
- Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 05/27/2024
|
The Ultimate Growth Stock to Buy With $20 Right Now
- Hims & Hers has entered the popular GLP-1 agonist category. Weight loss has quickly become a significant, potentially unexpected catalyst.
- 05/26/2024
|
7 Stocks to Dominate in the Next Economic Upturn
- If you're wondering which stocks to buy for the next economic upturn, you're in the right place. Finding profitable investment opportunities in the constantly changing global economy is crucial to profiting from the next economic boom.
- 05/24/2024
|
The Growth Stock Shuffle: 2 to Ditch and 1 to Own
- Judging which growth stocks are good long-term bets is trickier than you might expect. These fast-moving businesses can be hard to forecast, and changes in their broader industries could quickly lift up (or sink) these growth names in short order.
- 05/22/2024
|
Hims & Hers Is Changing the Game
- GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.
- 05/22/2024
|
Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy
- Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.
- 05/21/2024
|
Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages
- Hims & Hers Health got a shot in the arm this week that sent its share prices to near all-time highs.
- 05/21/2024
|
Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
- Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs. The company aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound, which are expected to dominate a potential $100 billion industry. Hims & Hers' partnership with a manufacturer of generic and compounded medications allows it to offer these drugs without supply shortages, potentially generating significant revenue.
- 05/21/2024
|
Weight loss drug roll-out sends Hims & Hers stock soaring
- Weight loss drugs helped Hims & Hers Health (NYSE:HIMS) put value on, with the stock soaring some 30% higher in ‘afterhours' trade on Monday. The online consumer healthcare brand last night announced it will sell lower-priced GLP-1 weight loss injectables and oral weight loss medication in the United States, through a deal with its pharmacy supplier.
- 05/21/2024
|
Celebrity Fitness Trainer Jillian Michaels weighs in on Hims & Hers offering weight-loss drugs
- Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
- 05/20/2024
|
Dr. Craig Primack talks Hims & Hers launching its own GLP-1 offering as demand rises
- Dr. Craig Primack, Hims & Hers SVP of Weight Management, joins 'Closing Bell Overtime' to talk the company offering a GLP-1 drug through its platform.
- 05/20/2024
|
Hims & Hers Health Stock Jumps Nearly 28% on Plans to Offer GLP-1 Weight-Loss Drugs
- Shares of Hims & Hers Health (HIMS) surged close to 28% Monday after the telehealth company said it would begin offering GLP-1 injections as part of its weight-loss package of drugs.
- 05/20/2024
|
Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy
- Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments.
- 05/20/2024
|
Three-Stock Lunch: Microsoft, Johnson Controls and Hims & Hers Health
- David Trainer, New Constructs CEO, joins 'Power Lunch' to discuss plays for three stocks: Microsoft, Johnson Controls, and Hims & Hers Health.
- 05/20/2024
|
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
- Shares of Hims & Hers Health (NYSE: HIMS ) stock are skyrocketing higher by over 25% after the telehealth company announced that it would provide access to GLP-1 weight-loss injections. Hims & Hers has partnered with an undisclosed manufacturer of generic and 503B compounded injectable medications to provide the injections.
- 05/20/2024
|
Hims & Hers Adds Weight-Loss Injections, Stock Soars
- Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 29.4% to trade at $18.85 and earlier hitting a three-year high of $20.11.
- 05/20/2024
|
Hims & Hers rallies after announcing access to GLP-1 injections
- Hims & Hers Health Inc shares rocketed 31% higher on Monday after announcing it will provide access to injectable GLP-1 medications. These injections serve as a more affordable alternative to branded versions such as Wegovy and Ozempic, said the telehealth company in a press statement.
- 05/20/2024
|
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
- Hims & Hers Health Inc.'s stock HIMS, +32.81% jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded GLP-1 drugs — products that the Food and Drug Administration has warned against.
- 05/20/2024
|
Tech Surge Boosts Nasdaq to Record Highs
- Tech Surge Boosts Nasdaq to Record Highs The S&P 500 is wavering below all-time highs as well Laura McCandless Deputy Editor May 20, 2024 at 11:48 AM SPX|IXIC|DJI All three major indexes are higher midday The Nasdaq Composite Index (IXIC) is up triple digits and marking new record highs, thanks to rising tech stocks. Nvidia (NVDA), specifically, is in focus as analysts throw in bull notes ahead of this week's earnings report. The Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) are enjoying more modest gains, though the latter is nearing its own all-time highs. Meanwhile, bond yields are also rising, amid comments from several Fed officials regarding inflation. Continue reading for more on today's market, including: Elliott built a $1 billion-plus stake in this electrical stock. Morgan Stanley upgrades Micron Technology stock. Plus, options traders target HIMS; DYN soars on trial data; and Li Auto's earnings disappoint. Options bulls are blasting Hims & Hers Health Inc (NYSE:HIMS), after the healthcare platform added GLP-1 injections to its weight-loss services, a compounded and cheap version of Novo Nordisk's (NVO) semaglutide (the active ingredient in Wegovy). So far, 100,000 calls have been exchanged -- 18 times the call volume typically seen at this point -- in comparison to 26,000 puts. The weekly 5/24 20-strike call is the most popular by far, where new positions are being opened. At last glance, HIMS was up 29.5% at $18.87, earlier hitting a three-year peak of $20.11. Dyne Therapeutics Inc (NASDAQ:DYN) is up 24.5% at $34.46 at last glance, after the biotech reported positive data for its muscular dystrophy treatments. In response, H.C. Wainwright raised its price target to $48 from $36, while Jefferies lifted its price objective to $42 from $36. Today's pop has DYN soaring to record highs, up 157.9% since the start of 2024. Meanwhile, the shares of Li Auto Inc (NASDAQ:LI) are trading at 52-week lows, down 14.1% at $21.37, after the China-based electric vehicle (EV) stock's disappointing first-quarter results. On the short sell restricted (SSR) list amid the volatility, LI is down roughly 43% year to date. Follow @Schaeffers (function () { var po = document.createElement('script'); po.type = 'text/javascript'; po.async = true; po.src = 'https://apis.google.com/js/platform.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(po, s); })();
- 05/20/2024
|
The case for the overvalued Hims & Hers stock
- Hims & Hers Health (NYSE: HIMS) stock price is doing well, helped by its strong growth and demand for its core products. It soared by over 30% this year and by more than 112% this year.
- 05/20/2024
|
Is Hims & Hers Health (HIMS) a Buy as Wall Street Analysts Look Optimistic?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 05/20/2024
|
Hims & Hers Health adds compounded GLP-1 injections to weight loss program
- The GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.
- 05/20/2024
|
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment. The company now offers access to GLP-1 injections in addition to weight management oral medication kits, so that customers can truly personalize their weight loss experience. Providing access to compoun.
- 05/20/2024
|
Stock Market Mayhem: 3 Companies Ready to Shake Things Up
- With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding.
- 05/20/2024
|
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
- IDEXX Laboratories' (IDXX Quick QuoteIDXX - Free Report) business has been suffering due to complex macroeconomic conditions and unfavorable currency movement. The stock carries a Zacks Rank #4 (Sell) currently.Global macroeconomic conditions, including growing geopolitical complexities, supply chain disruptions leading to increases in the unit cost of raw materials, shortages of healthcare staff, fluctuations in foreign currency exchange rates and volatility in capital markets may continue to affect IDEXX’s results of operations. These challenges, along with geopolitical instability, including the current war in Ukraine, have affected IDEXX’s supply chain operations globally. With sustained inflationary pressure in the future, the company may struggle to keep in check its cost of revenues and operating expenses.During the first quarter of 2024, IDEXX saw a significant 31.3% uptick in general and administrative expenses. Further, U.S. clinical visit growth levels in the first quarter were relatively softer than anticipated, which is likely due to the ongoing staffing challenges at veterinary clinics and broader cumulative macroeconomic pressure on U.S. consumers. Further, the majority of IDEXX's consolidated revenues are from product sales in international markets, with approximately 21% of total revenues in 2023 derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies. Thus, the strengthening of the rate of exchange for the U.S. dollar relative to other currencies had a negative impact on the company’s revenues derived in currencies other than the U.S. dollar and on profits from products manufactured in the United States and sold internationally. In 2023, foreign exchange reduced operating profits by $25 million (operating margin gains by 60 basis points) and EPS by 24 cents per share.During the first quarter of 2024, it had a limited impact on gross margin, operating profit and EPS. IDEXX’s updated 2024 revenue forecast includes a $35 million impact, equivalent to about a 1% decrease, due to the recent appreciation of the U.S. dollar.IDEXX Laboratories, Inc. Price IDEXX Laboratories, Inc. price | IDEXX Laboratories, Inc. QuoteHowever, IDEXX is focused on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. In late 2023, the company expanded its operations in the United States for the first time in four years, complementing the seven international expansions it has advanced since 2021. Through these strategic investments, the company continues to strengthen its growth prospects by delivering high-touch commercial engagement in the fastest-growing regions while maintaining strong business performance. This expanded global commercial capability is yielding strong results overseas, with notable 12% organic growth in international CAG diagnostic recurring revenues in the first quarter of 2024. Diagnostics has been one of the fastest-growing areas of the veterinary clinic for IDEXX since the determination of a patient's health status and the best treatment path often requires testing. IDEXX largely provides advanced diagnostic capabilities that meet veterinarians’ diverse needs through a variety of modalities, including in-clinic diagnostic solutions and outside reference laboratory services. These diagnostic capabilities generate a mix of recurring and non-recurring revenues.Key PicksSome better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS - Free Report) , High Tide (HITI Quick QuoteHITI - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) . Each of them sports a Zacks Rank #1 (Strong Buy) at present. Hims & Hers Heath stock has rallied 53.3% in the past year. Earnings estimates for the company have risen from 10 cents to 18 cents in 2024 and from 23 cents to 32 cents in 2025 in the past 30 days.HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.Estimates for High Tide’s 2024 earnings per share have remained unchanged in the past 30 days. Shares of the company have surged 57.9% upward in the past year against the industry’s fall of 0.6%.HITI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 91.7%. In the last reported quarter, it delivered an earnings surprise of 100%.Estimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $10.53 in the past 30 days. Shares of the company have risen 87.6% in the past year compared with the industry’s 5% growth.MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
- 05/20/2024
|
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official. “Anja is a remarkable leader and v.
- 05/16/2024
|
Earnings Estimates Rising for Hims & Hers Health (HIMS): Will It Gain?
- Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 05/15/2024
|
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
- Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 05/15/2024
|
3 Stocks That Suddenly Drew in Options Traders
- Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, others could use them to express their predictions on a particular stock.
- 05/13/2024
|
Is Hims & Hers Health Stock a Buy?
- Hims & Hers stock is down after some political comments by the CEO. However, Q1 earnings remind investors why the business is so good.
- 05/13/2024
|
Hims & Hers Health Shares Climb After News of Double-Digit Revenue Growth. Is It Too Late to Buy the Stock?
- Hims reported strong Q1 results that saw revenue surge 46% year over year. The stock fell after some controversial comments from its CEO, but he recently walked them back.
- 05/11/2024
|
5 Medical Info Systems Stocks to Buy for Stable Returns
- We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
- 05/10/2024
|
10 Solid Reasons To Buy Hims & Hers Stock
- It's been a wild week for HIMS stock — CEO Andrew Dudum said a few things that upset investors. H&H also reported blowout earnings, sending shares higher. People quickly forget that H&H is a brilliant company.
- 05/09/2024
|
Hims & Hers Health (HIMS) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Hims & Hers Health (HIMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 05/08/2024
|
Best Momentum Stock to Buy for May 8th
- HIMS, CHRW and WRK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 8, 2024.
- 05/08/2024
|
2 Incredible Growth Stocks to Buy Hand Over Fist
- Growth stocks are experiencing a multi-decade bull run at the moment. Kura Oncology and Hims & Hers are two red-hot growth stocks worth checking out right now.
- 05/08/2024
|
3-Stock Lunch: PLTR, HIMS & GPS
- Courtney Garcia, Payne Capital Management senior wealth advisor, to discuss investment plays for three stocks including; Palantir, Hims and Hers Health Inc. and Gap.
- 05/07/2024
|
Why Hims & Hers Health Stock Popped 17.1% Today
- Strong revenue growth continued as the number of users increased 41%. Profits are coming in faster than expected for a company still concerned with growing the top line.
- 05/07/2024
|
Telehealth Stock Gains Popularity With Options Bulls
- Options bulls are blasting Hims & Hers Health Inc (NYSE:HIMS) stock today, with 33,000 calls exchanged so far -- 8 times the intraday average volume -- compared to 11,000 puts.
- 05/07/2024
|
Hims & Hers Health Stock Could Become a Wealth Compounder
- Shares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings results. This quarter is arguably the most important quarter as it sets the tone for the rest of the year in any stock.
- 05/07/2024
|
Hims & Hers Health, Inc. (HIMS) Q1 2024 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder and CEO Yemi Okupe - CFO Conference Call Participants Allen Lutz - Bank of America Maria Ripps - Canaccord Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Korinne Wolfmeyer - Piper Sandler George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers First Quarter 2024 Earnings Conference Call.
- 05/06/2024
|
Hims & Hers Health, Inc. (HIMS) Q1 Earnings and Revenues Top Estimates
- Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago.
- 05/06/2024
|
Hims & Hers shares rally as forecast bumped higher and more profitability said to be ahead
- Shares of Hims & Hers Health Inc. rose after hours on Monday after the online wellness platform bumped its full-year sales forecast higher, following sharp increases in subscribers and profits during the first quarter, as it tries to provide more personalized treatments.
- 05/06/2024
|
Hims & Hers CEO walks back praise for anti-Israel protesters after stock drops
- Hims & Hers founder and CEO Andrew Dudum said Sunday that his earlier comments praising anti-Israel protesters on college campuses were "misconstrued by some."
- 05/06/2024
|
Hims & Hers stock slides after CEO's praise for anti-Israel protesters
- Hims & Hers Health stock declined Friday by about 8% after CEO Andrew Dudum's praise for anti-Israel campus protesters in a social media post last week.
- 05/04/2024
|
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
- Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
- 05/03/2024
|
Bears are Losing Control Over Hims & Hers Health (HIMS), Here's Why It's a 'Buy' Now
- After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 05/03/2024
|
Why Hims & Hers Health, Inc. (HIMS) Outpaced the Stock Market Today
- Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $12.50, signifying a +1.87% move from its prior day's close.
- 04/26/2024
|
Why Hims & Hers Stock Was Down This Week
- The stock had had quite the run-up in price before its slide. Investors were extremely satisfied with the fourth-quarter earnings report published in February.
- 04/19/2024
|
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
- Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $12.34, moving -0.56% from the previous trading session.
- 04/18/2024
|
Investing in Growth: 2 Top-Ranked Stocks with Huge Potential
- Strong sales growth is a beacon for investors seeking promising companies. It often indicates a product or service has struck a chord with the market, generating significant customer demand.
- 04/18/2024
|
The Disruptor's Portfolio: 3 Stocks Shaping the New Economy
- Innovative technology and strategic alliances drive industries ahead. These three disruptive stocks are among the pioneers influencing the economy of the future.
- 04/17/2024
|
Hims & Hers to Announce First Quarter 2024 Financial Results on May 6, 2024
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers," NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2024 financial results after the market closes on Monday, May 6, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenci.
- 04/15/2024
|
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
- In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $14.60, denoting a +0.34% change from the preceding trading day.
- 04/11/2024
|
Got $2,000? 2 Unbelievable Growth Stocks Up 58% and 30% to Buy in the New Bull Market
- These stocks are reporting above-average growth rates in their respective industries and share prices are soaring. Hims & Hers Health is serving essential needs across diverse patient populations.
- 04/06/2024
|
3 Stocks With Unusual Call Option Activity
- When traders stampede into call options, it typically means they expect an event to come, pushing the underlying stock higher soon. Because options expire at a given date, these traders must get their thesis right before expiration or risk losing their entire investment.
- 03/26/2024
|
Hims & Hers Health: A Lesson In Psychology
- Younger generations need digital healthcare solutions. Hims' birth and ascent is a lesson in psychology. I disclose my original position of just under 50,000 shares at a cost basis of $5.50. I value Hims using a DCF and EPS table so investors will have a clear picture of my valuation and can calculate their own from my table.
- 03/18/2024
|
3 Stocks That Could Benefit from the Rise of Telemedicine
- With the growing demand for telemedicine, the market could be worth about $450 billion by the time 2032 rolls around. That's according to Emergen Research.
- 03/14/2024
|
3 Market-Disrupting Stocks Primed for a 400% Leap in the Next 2 Years
- In the dynamic market, certain stocks emerge as titans. They are disrupting traditional markets and hold meteoric growth potential.
- 03/13/2024
|
Can WeightWatchers Regain Its Mojo after Oprah Steps Down?
- WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.
- 03/13/2024
|
Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
- Hims & Hers Health, Inc. has grown from a startup ($82m revenues in 2019) to a multi-billion-dollar company ($872m revenues in 2023) with more than 1.5 million subscribers; showcasing its scalability and product development. Hims & Hers Health achieved its first GAAP profitable quarter and provided strong 2024 guidance. Hims & Hers has improved its marketing efficiency, reducing the payback period for marketing expenses, demonstrating effective customer acquisition strategies.
- 03/12/2024
|
3 Meme Stocks that r/WallStreetBets Loves (but Shouldn't!)
- GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) saw their shares skyrocket in early 2021 after several Reddit users incited a rally. Investors may have largely lost interest in these two stocks.
- 03/10/2024
|
Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade
- In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the listed tech titans to emerge as veritable champions.
- 03/08/2024
|
What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?
- Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 03/05/2024
|
Hims & Hers Stock Rises On Stimulating Earnings Growth
- Hims & Hers Inc. NYSE: HIMS is a telehealth platform in the medical sector that has turned the corner into GAAP profitability. The company got its start offering convenient, frictionless and discreet erectile dysfunction (ED) prescription solutions for men but has since expanded its offering into primary care and health and wellness products, including weight loss solutions for men and women.
- 03/05/2024
|
Healthcare stock up 50% in 2024, and it might be just the beginning
- The shares of Hims & Hers Health (NYSE: HIMS), a direct-to-consumer telehealth company, have surged by more than 40% since the release of its Q4 earnings report and more than 50% since the start of the year.
- 03/05/2024
|
The Top 7 Small-Cap Stocks to Buy in March 2024
- Small-cap stocks haven't quite caught up to wider investor sentiment, but that trend is set to change. While large- and mega-caps like those within the S&P 500 survived and, in many cases, thrived, over the past year, small-cap indices like the S&P 600 underperformed — 26%+ and 5.5%, respectively.
- 03/04/2024
|
Hims & Hers Health Surges 30% After Earnings. Here Is Why the Stock Is Still a Magnificent Buy.
- Hims & Hers Health is up big on a blowout Q4 earnings report. The company is taking market share from competitors.
- 03/03/2024
|
3 Telehealth Stocks With Room to Run in 2024
- While telehealth stocks, once stars of the pandemic era, have seen a recent dip in investor interest, savvy investors recognize the sector's bright future. Moreover, according to TalkSpace (NASDAQ: TALK ) CEO Jon Cohen, it could be argued that the pandemic catapulted telehealth forward by a decade, ushering in a new era of at-home primary and specialty care demanding investor attention.
- 02/29/2024
|
Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge
- Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 02/29/2024
|
This healthcare stock making a buzz with 160% growth
- Investing in healthcare stocks may not seem very exciting. This group of low-beta stocks serves as a defensive area of the consumer staples sector without much growth or activity.
- 02/29/2024
|
Hims & Hers soars 32% on rapid growth in mental health, weight loss and dermatology treatments
- Shares of Shares of Hims & Hers Health popped Tuesday after the company reported better-than-expected quarterly results.
- 02/27/2024
|
Hims & Hers (HIMS) Hits 52-Week High After Earnings
- Hims & Hers (HIMS) soars after earnings. Renita Young discuss this as Hims & Hers hit a new 52-week high after earnings.
- 02/27/2024
|
Hims & Hers' stock jumps on hopes of first profitable year, as it floats opportunities in weight loss
- Shares of Hims & Hers Health Inc. rallied after hours on Monday, after the online wellness platform said 2024 would be its first year of positive net income and forecast first-quarter and full-year sales that were above expectations.
- 02/26/2024
|
Hims & Hers: Turning The Profitability Corner And Returning 28%
- Hims & Hers Health stock has rallied over 50% since our previous "Strong Buy" article, but the stock may be overextended, and earnings are approaching. The company's subscription model, market opportunity, and undervalued multiple were the main reasons for our original bullish thesis, and remain relevant today. Recent updates show strong revenue growth, improving economics, and continued execution of a successful land & expand strategy, but the stock's performance may be reflecting these positives.
- 02/25/2024
|
Unlocking Growth: Why Hims & Hers Stock Is A Very Compelling Buy In 2024
- Hims & Hers Health is a telehealth company with a unique approach to accessible healthcare solutions. The company operates in a large and diverse TAM, allowing for multiple players to thrive and innovate. HIMS has exhibited robust financial performance, with strong revenue growth and profitability prospects.
- 01/29/2024
|
3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024
- Small-cap healthcare stocks might be the next stock market goldmine, but many investors are overlooking the sector's potential. Small-cap healthcare stocks tend to be nimbler and more innovative than their blue-chip counterparts (with some exceptions), meaning they're better equipped to navigate tricky market conditions and changing industry trends.
- 01/25/2024
|
7 Growth Stocks to Buy and Hold Forever: January 2024
- Even as the S&P 500 marks new highs, many top growth stocks haven't seen the same momentum. Since most of the recent market gains come from just a handful of leading stocks, hidden opportunities in growth stocks abound.
- 01/23/2024
|
Where Will Hims & Hers Stock Be in 5 Years?
- Hims & Hers aims to destigmatize certain aspects of healthcare while making access to care more convenient. The company's massive growth rate and burgeoning profitability could reward investors over the coming years.
- 01/15/2024
|
3 Stocks to Profit from the Telehealth Transformation
- Telehealth stocks fell off the collective radar somewhat post-pandemic. But betting against the sector isn't smart because healthcare's future is undoubtedly anchored in virtual offerings for routine and non-emergent care.
- 01/12/2024
|
Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?
- Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/03/2024
|
Underestimating This Stock Could Be Wall Street's Biggest Mistake in 2024
- Analysts believe Hims & Hers Health will lose money in 2024. But comments from the CEO signal this could be wrong.
- 01/02/2024
|
The 3 Hottest Telehealth Stocks to Watch in 2024
- The telehealth sector will effectively reshape the medical services market in 2024. As a hotbed for innovation, it's attracting investors with its potential in a burgeoning market.
- 01/01/2024
|
Hims & Hers Health: Faultless, Ready To Go Higher
- Hims & Hers Health: Faultless, Ready To Go Higher
- 12/19/2023
|
Hims & Hers Health: Promising Catalysts To Drive Stock Higher
- Hims & Hers Health has reported strong quarterly results and improved profits, leading to a stock snapback. The company is moving into AI-based medical services and weight loss management to address soaring costs. The stock is incredibly cheap trading at less than 2x sales while forecast to top 20% growth for years ahead.
- 12/17/2023
|
Hims & Hers Health Q3: The Cheapest Growth Stock Around
- Hims & Hers Health raised its guidance once again when it reported its Q3 results. The company saw significant growth in subscribers, particularly in the mental health and women's health sectors. HIMS is one of the cheapest growth stocks around.
- 12/14/2023
|
My 2024 Financial Resolution: Buying More of These 3 Stocks
- SentinelOne keeps delivering cutting-edge tech and strong growth. Roku is an entrenched streaming leader with future growth ahead.
- 12/11/2023
|
1 Healthcare Stock to Buy Hand Over Fist Going Into 2024
- Hims & Hers Health is a telemedicine company specializing in a variety of treatments. The company's unique subscription model has helped propel strong top-line growth and margin expansion.
- 12/08/2023
|
Ozempic vs. Mounjaro:: Battle of the bulge
- The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Novo Nordisk A/S NYSE: NVO Semaglutide drug Ozempic to go mainstream and viral as countless consumers try the medication that was originally approved for type 2 diabetes patients.
- 12/04/2023
|
Hims & Hers Health: What Would The Author Of 100 Baggers Say?
- Hims & Hers Health exhibits similarities to previous "100 Bagger" stocks, which I believe the market has not noticed at all. I wanted to bring this to the forefront. The company has the potential to be a transformative force in healthcare, with accelerating top-line growth, expanding margins, and a sticky subscriber base. HIMS has strong fundamentals, including profitability potential, high gross margins, value-added services, strong sales growth, and a growing subscriber base.
- 11/30/2023
|
This Growth Stock Could 10x in 10 Years
- Hims & Hers Health has performed at a high level since going public. The company is nearly profitable despite investing heavily for revenue growth.
- 11/29/2023
|
Hims & Hers earnings highlight expanded personalized treatments
- E-health and wellness platform operator Hims & Hers Inc. NASDAQ: HIMS reported a stellar quarter of growth. The company has expanded its medical offerings well beyond offering discrete erectile dysfunction (ED) medication and sexual health products.
- 11/29/2023
|
5 Telehealth Stocks That Have Nothing But Upside
- The telehealth sector is undergoing a significant transformation, reshaping the traditional contours of medical service delivery. This innovation-driven domain is drawing attention from investors, as top telehealth stocks show potential in a rapidly expanding market.
- 11/26/2023
|
My Take: 4 Strong Growth Stocks to Buy This Week
- The stock market has performed well in recent weeks. Rising stock prices make finding good deals harder.
- 11/26/2023
|
2 No-Brainer Stocks to Buy Right Now for Less Than $50
- Well-chosen stocks can help you build lasting wealth. Read on to see how you could profit from the AI boom, as well as the shift toward more personalized healthcare.
- 11/24/2023
|
2024's Hidden Gems: 7 Small-Caps Set for Explosive Growth
- Finding a great small-cap stock to buy isn't always easy. We know that, over the long run, small-cap stocks as a whole outperform large-cap cousins.
- 11/23/2023
|
Is Hims & Hers Stock a Buy Now?
- Hims & Hers reported another strong quarter this month as its growth rate remains above 50%. The company raised its forecast for the year as well.
- 11/16/2023
|
Is Hims & Hers Health Stock a Buy After Strong Earnings?
- The company reported another good quarter and announced a buyback. Is HIMS stock a buy?
- 11/07/2023
|
Hims & Hers Health, Inc. (HIMS) Q3 2023 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Alice Lopatto - VP, IR Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - CFO Conference Call Participants Glen Santangelo - Jefferies Daniel Grosslight - Citigroup Jack Wallace - Guggenheim Securities Jailendra Singh - Truist Securities Allen Lutz - Bank of America Merrill Lynch George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Third Quarter 2023 Earnings Conference Call.
- 11/06/2023
|
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates
- Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
- 11/06/2023
|
Hims and Hers narrows loss, raises revenue guidance for the year
- Shares of Hims & Hers Health Inc. HIMS, -3.09% rose more than 3% in the extended session Monday after the telehealth company narrowed its quarterly loss and raised its sales guidance for the year, saying its “personalized” health offerings are resonating with people. Hims lost $7.6 million, or 4 cents a share, in the third quarter, which met FactSet consensus and compared with a loss of $18.8 million, or 9 cents a share, in the third quarter of 2022.
- 11/06/2023
|
Hims & Hers: A Promising Company With Resolvable Challenges
- While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major risks revolve around customer service issues, rising customer acquisition costs, and potential challenges in retaining customers due to branding and personalization concerns. With a proactive approach to addressing customer concerns and fine-tuning its operational strategies, Hims & Hers has the potential to overcome these challenges and thrive in the telehealth market.
- 11/02/2023
|
Hims & Hers: Specialization Is The Secret To Great Growth
- Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skincare, acne, and mental health. The company has experienced impressive revenue growth and margins, driven by online sales and a growing subscriber base of over 1.3 million customers. Hims & Hers Health is investing in AI and data analysis to enhance personalized treatments and is exploring new market opportunities, such as weight management.
- 10/24/2023
|
Where Will Hims & Hers Health Be in 5 Years?
- Hims & Hers continued to grow at an impressive rate of more than 80% last quarter. The telehealth company has been expanding into more areas of healthcare.
- 10/19/2023
|
Is Hims & Hers Health Stock a Buy Now?
- Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet.
- 10/03/2023
|
Rocket Stocks: 3 Investments Primed to Skyrocket by Year's End
- Some companies stand out as genuine contenders for explosive growth and substantial gains in the stock market. The article lists three stocks to buy now that have thrived thanks to their innovative strategies and adaptability in the face of change.
- 09/27/2023
|
2 Beaten-Down Growth Stocks That Could Rocket 107% to 127% Higher, According to Wall Street
- Consensus price targets from Wall Street analysts suggest a pair of healthcare stocks can more than double your money. Hims & Hers Health runs an increasingly popular niche telehealth platform where patients can get their prescriptions written and filled.
- 09/26/2023
|
Hims and Hers Stock Analysis: Buy or Sell?
- The healthcare company is demonstrating excellent revenue growth.
- 09/22/2023
|
Hims & Hers Health: Risks Remain, But Upgrading To Buy
- Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization and expanding into new categories to drive growth. While the risks are evident, the company's growth and valuation make it a speculative "Buy."
- 09/20/2023
|
Hims & Hers: Myopic Shorts, Absurdly Cheap
- Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report questions Hims' ability to turn customer acquisition into profitability, but recent financial data shows promising revenue and gross profit growth. While Hims may not have a strong brand equity or an impenetrable moat, its approach and million paying subscribers make it a compelling investment.
- 09/20/2023
|
2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Beauty stocks have not been pretty this year. Cosmetics retailer Ulta Beauty Inc. NASDAQ: ULTA and Estee Lauder Co. NYSE: EL shares are trading down 12.3% and 38.7%, respectively.
- 09/19/2023
|
The Market Is Wrong On Hims & Hers Health
- Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SPAC. The company is targeting lofty growth targets for years to come and has plans to expand in many new markets while maintaining gross profits near 80%. The current valuation is rather low at a P/S of just 1.8. The risk-reward profile for an entry point seems very favourable at the moment.
- 09/17/2023
|
Is This Underrated SPAC Deal Stock a No-Brainer Buy?
- Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%.
- 09/06/2023
|
This Fast-Growing Company Is the Latest to Launch a Weight-Loss Business
- The market for weight management could be worth close to $300 billion by the end of the decade. Hims & Hers is planning to launch a weight-loss business by January.
- 08/23/2023
|
Hims & Hers: Buying With Both Fists (Double Rating Upgrade)
- Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories such as heart health and weight management. We believe HIMS stock is undervalued, and current prices present a buying opportunity.
- 08/21/2023
|
Hims & Hers: Divergence Between Fundamentals And Valuation
- Q2 Revenue beat analyst estimates by $3M. Gross Margin improved despite price cuts. Management raised guidance by $20M, which also beat estimates by $19M.
- 08/16/2023
|
Could Hims & Hers Health Stock Help You Become a Millionaire?
- Hims & Hers Health keeps turning in stellar operating results. But shares have slid 30% over the past few months.
- 08/13/2023
|
Is Hims & Hers Health Stock a Must Buy Under $10?
- This potential multibagger stock is being underappreciated by the market. Here's why Hims & Hers stock is a buy right now.
- 08/09/2023
|
Hims & Hers Health, Inc. (HIMS) Q2 2023 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President, Investor Relations Andrew Dudum - Co-Founder & Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities Michael Cherny - Bank of America Glen Santangelo - Jefferies Jungwon Kim - Cowen Jonathan Young - Credit Suisse Jailendra Singh - Truist Securities George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Ivan Feinseth - Tigress Financial Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2023 Earnings Conference Call.
- 08/07/2023
|
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
- Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.10 per share a year ago.
- 08/07/2023
|
Hims & Hers stock jumps 13% after narrower loss in Q2
- Hims & Hers Health Inc. HIMS, -3.07% shares rallied nearly 13% in the aftermarket Monday after the telehealth company reported a narrower-than-expected loss for its second quarter and revenue that was above expectations. Hims & Hers lost $7.2 million, or 3 cents a share, in the quarter, compared with $19.7 million, or 10 cents a share, in the second quarter of 2022.
- 08/07/2023
|
Hims & Hers to Announce Second Quarter 2023 Financial Results on August 7, 2023
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2023 financial results after the market closes on Monday, August 7, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refer.
- 07/24/2023
|
Hims & Hers: Market Blows Off Short Report
- Spruce Capital Management issued a short report on Hims & Hers Health, Inc., but the call actually only forecast downside risk to $5. The health and wellness company continues to grow at a fast clip while expanding the market opportunity beyond the initial ED category. The stock rallied on the news, with Hims already beaten down this year and trading at a cheap valuation.
- 07/14/2023
|
The More This Potential Multibagger Stock Drops, The More I Buy
- Hims & Hers Health stock has fallen since its last earnings report. Wall Street could be misinterpreting the company's high marketing spend.
- 07/13/2023
|
2 Hot Stocks Up 30% This Year That Wall Street Thinks Can Still Go Higher
- Hims & Hers has a booming telemedicine business that could grow by 57% this year. Viking Therapeutics has a promising pipeline that features a couple of potential blockbuster drugs.
- 07/12/2023
|
How to Find the Best Cheap Stocks Under $10 to Buy in July
- Today we dive into a pocket of the stock market that many investors like to own as part of diversified portfolios: cheap stocks trading for $10 a share or less. Along with the cheap price tag, the stocks we explore today boast high Zacks Ranks given their improving earnings outlooks.
- 07/11/2023
|
7 Small-Cap Stocks That Have Insiders Running for the Exit
- Given the riskier and more speculative nature of small-cap stocks, if you own a stock in this category, it's important to keep an eye out for signs that said name has become one of the small-cap stocks to sell. A key warning sign to look out for is insider selling.
- 06/26/2023
|
My 3 Favorite Stocks Right Now
- Amazon is still attractively valued for its growth potential. Hims & Hers isn't getting the respect it deserves.
- 06/16/2023
|
Hims & Hers: Sell-Off Opportunity
- Hims & Hers plunged after Q2 adjusted EBITDA guidance disappointed Wall Street. The online health and wellness company has massive growth opportunities ahead and continues investing aggressively in marketing to build its subscriber base. HIMS stock is a bargain below 2x '24 sales targets for a company forecasted to maintain 25% growth while constantly providing conservative estimates.
- 06/12/2023
|
Hims & Hers: More Transparency Could Help The Stock
- Hims & Hers stock has struggled despite strong Q1 earnings and raised full-year guidance, with shares down over 20% since the report. HIMS' subscriber count grew 87% YoY to 1.209 million, and it is investing in brand awareness to capture more business and move into other categories such as mental health and dermatology. Questions persist about the business model and expansion into other categories, with more transparency needed to make investors more comfortable with the stock.
- 06/09/2023
|
The Top Healthcare Stocks to Buy With $100
- Pfizer is an old dog with big new tricks to come in the pharmaceutical sector. CVS has expanded beyond pharmacies to include health insurance and more.
- 05/29/2023
|
Hims & Hers Stock: The Gift That Keeps On Giving
- Despite Hims & Hers delivering exceptional numbers on almost all KPI metrics, the stock has dipped by ~17.5% since the release of its Q1 report earlier this month. In this note, we will discuss Hims & Hers' Q1 2023 report and re-evaluate our fair value estimate for the company.
- 05/22/2023
|
This Healthcare Innovator Is Up 235% in 12 Months: There's More Where That Came From
- Direct-to-consumer healthcare is proving lucrative. This company is growing subscribers by 87% year over year.
- 05/13/2023
|
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
- Here is how Hims & Hers Health, Inc. (HIMS) and Apollo Medical Holdings, Inc. (AMEH) have performed compared to their sector so far this year.
- 05/11/2023
|
Hims & Hers Health, Inc. (HIMS) Q1 2023 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2023 Results Conference Call May 8, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President of Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Jack Wallace - Guggenheim Securities Dan Clark - Bank of America Glen Santangelo - Jefferies Korinne Wolfmeyer - Piper Sandler Luis Mario Higuera - Citi Jailendra Singh - Truist Securities Operator Ladies gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers First Quarter 2023 Earnings Conference Call.
- 05/08/2023
|
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates
- Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.
- 05/08/2023
|
Him & Hers raises full-year sales outlook, but stock falls
- Hims & Hers Health Inc. HIMS — the wellness company behind the online telehealth and prescription platforms Hims and Hers — on Monday reported a bigger per-share loss than expected for its first quarter, but raised its full-year sales forecast. The company — which offers erectile dysfunction pills, birth control, and anxiety and depression medications — said it expected full-year sales of $810 million to $830 million, compared with an earlier outlook for $735 million to $755 million and FactSet forecasts for $755.3 million.
- 05/08/2023
|
Could Hims & Hers Health Stock Help You Become a Millionaire?
- Hims & Hers Health is putting up eye-popping growth. There's plenty of room for long-term expansion.
- 04/22/2023
|
Hims & Hers Health, Inc. (HIMS) Surges 10.3%: Is This an Indication of Further Gains?
- Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/19/2023
|
Hims & Hers to Announce First Quarter 2023 Financial Results on May 8, 2023
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2023 financial results after the market closes on Monday, May 8, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S.
- 04/17/2023
|
Hims & Hers: I Might Buy The Rally
- Hims & Hers has maintained an extremely strong pace of revenue growth to reenergize previously flagging investor sentiment. Whilst its forward price-to-sales multiple has risen to eclipse most of its peers, HIMS is growing quickly.
- 04/12/2023
|
5 Best and Worst Performing Mid-Cap Stocks in February 2023
- Mid-cap stocks offer a balance between stability and growth prospects. On the one hand, they offer better growth prospects than large-cap stocks, and on the other, they carry lower risk and more stability than small-cap companies.
- 03/09/2023
|
Investors Cash In On 12 'Triple Play' Stocks That Do No Wrong
- Investors are worried that S&P 500 stocks will let them down. So why not focus on the handful that are delivering perfection?
- 03/07/2023
|
Hims & Hers Health: Proposed Telemedicine Regulation Could Materially Impact Sales
- I previously rated HIMS as a buy and also mentioned the idiosyncratic regulatory risk the company is facing as a telemedicine operator. This has now come to fruition, with a new regulatory framework put on the table as of last Friday 2/24/23.
- 03/07/2023
|
Not All Growth Stocks Are Dead With Austin Hankwitz (Cash Flow Freaks)
- We're joined by Austin Hankwitz from Cash Flow Freaks on Seeking Alpha. We dive into the Hims & Hers Health earnings report that was just announced.
- 03/01/2023
|
Hims & Hers stock rises following fourth quarter earnings beat
- The Yahoo Finance's Dave Briggs and Seana Smith discuss Hims & Hers' latest earnings release and the movement in the company's stock.
- 02/28/2023
|
Hims & Hers: We're seeing ‘continued strong momentum,' CFO says
- #Hims&Hers Hims & Hers CFO Yemi Okupe joins Yahoo Finance Live anchors Brad Smith and Julie Hyman to discuss company earnings, competition in the wellness industry, and the outlook for growth opportunities.
- 02/28/2023
|
Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates
- Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 28.57% and 4.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
Hims & Hers Health, Inc. (HIMS) Q4 2022 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President of Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Ben Clark - Bank of America Daniel Grosslight - Citi Jack Wallace - Guggenheim Glen Santangelo - Jefferies Jonathan Yong - Credit Suisse Jonna Kim - Cowen George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Ivan Feinseth - Tigress Financial Joy Zhang - SVB Securities Operator Good afternoon ladies and gentlemen, welcome to the Hims & Hers Health Fourth Quarter 2022 Earnings Call. My name is [indiscernible], and I will be your operator today.
- 02/27/2023
|
Stocks moving in after hours: Occidental Petroleum, Hims & Hers Health, Workday, Meta
- Yahoo Finance anchor Seana Smith takes a look at some of the biggest movers in after-hours trading.
- 02/27/2023
|
Hims and Hers stock rallies after Q4 beat, subscriber data
- Shares of Hims & Hers Health Inc. HIMS, -1.23% rose more than 9% in the after-hours session Monday after the telehealth company reported narrower fourth-quarter results and revenue that was above expectation. Hims and Hers lost $10.9 million, or 5 cents a share, in the quarter, compared with a loss of $31.2 million, or 15 cents a share, for the fourth quarter of 2021.
- 02/27/2023
|
Why Hims & Hers Health Stock Was so Healthy This Week
- Investors take an analyst's very positive change in sentiment to heart.
- 02/10/2023
|
Hims & Hers: Profitability Pulled Forward
- Hims & Hers pulled forward its profitability. HIMS is now expected to be EBITDA profitable in Q4 2022, months ahead of schedule.
- 01/25/2023
|
Hims & Hers Health: Buy Into The Strong Growth Momentum
- Telehealth is gaining strong adoption momentum amongst younger generations. HIMS has a very attractive business model.
- 01/18/2023
|
Top Wall Street analysts like these stocks amid easing inflation
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, including Alphabet & Intuitive Surgical
- 01/15/2023
|
Hims & Hers Health: The Ultimate Pick For 2023
- Hims & Hers Health is a telehealth company which solves two major issues for patients in modern healthcare: it provides easier access to physicians and lower cost treatments. Hims is growing at a blistering pace and the company is expected to be EBIT positive for the first time in Q4 2022 and recently made a new 52-week high.
- 12/23/2022
|
Hims & Hers Health: The Unicorn (Former) SPAC For 2023
- Hims & Hers Health, Inc. blew their original 2022 financial projections out of the water. The company is a growth investor's dream: large TAM, predictable subscription revenue, tech-company margins, and soon-to-come free cash flow.
- 12/16/2022
|
Hims & Hers Health Seems Like A Great Pick For 2023
- Hims & Hers Health has demonstrated resilient margins and accelerating growth in 2022 with no signs of slowing down, supported by rapidly expanding telehealth market and good brand recognition. The company has a strong balance sheet with no debt and considerable cash and short term investments, eliminating the need for capital raising.
- 12/10/2022
|
5 Stocks That Could Double Your Money in 2023
- 100% gains in this market? It's not as crazy as it sounds.
- 12/02/2022
|
Worried About Amazon? Buy This Fast-Growing Stock Instead
- Hims & Hers is a small-cap stock that is on track to nearly double its revenue this year.
- 11/23/2022
|
Hims & Hers down more than 35% since trading debut in January
- CNBC's Bertha Coombs reports on high-flying health tech firms' stock performance.
- 11/19/2022
|
Better Growth Stock: Teladoc vs. Hims & Hers
- A showdown between two hot telehealth companies.
- 11/13/2022
|
Hims & Hers Health: Gobble Up Shares While You Can
- Hims posted another excellent quarter with record-breaking subscriptions and revenue. AOV, Retention Rates, and Churn Rates are all at impressive levels. Management delivered on its promises to scale up the business while providing great customer satisfaction. Multi-month subscriptions are increasing, resulting in more customer stickiness.
- 11/09/2022
|
Why Hims & Hers Health Stock Soared Today
- Profitability could come sooner than investors expected.
- 11/08/2022
|
Hims & Hers CFO: Business momentum is ‘some of the strongest we've seen'
- Hims & Hers CFO Yemi Okupe joins Yahoo Finance Live to discuss business and subscription growth, reaching more consumers, removing the stigma around sexual health and reproductive conditions, and weathering an economic downturn.
- 11/08/2022
|
Why Is Hims & Hers (HIMS) Stock Up 24% Today?
- Hims & Hers (NYSE: HIMS ) stock is climbing higher on Tuesday after reporting results for the third quarter of 2022. Investors are especially taking note of the company's newest guidance in that earnings report.
- 11/08/2022
|
Hims & Hers Health, Inc. (HIMS) Q3 2022 Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Christine Greany - The Blueshirt Group Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Daniel Grosslight - Citi Jonathan Young - Credit Suisse Korinne Wolfmeyer - Piper Sandler Michael Cherny - Bank of America Jack Wallace - Guggenheim Securities Maxi Ma - Deutsche Bank Joy Zhang - SVB Securities Operator Good afternoon, everyone, and welcome to the Hims & Hers Third Quarter 2022 Earnings Call. My name is Lisa, and I'll be your operator today.
- 11/07/2022
|
Here's Why Hims & Hers Health, Inc. (HIMS) Could be Great Choice for a Bottom Fisher
- After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health, Inc. (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 11/07/2022
|
This Stock Could 10X in 5 Years
- An assessment of the company's prospects reveal an ecouraging outlook.
- 11/02/2022
|
Hims & Hers Looks Extremely Cheap, I Am Buying
- HIMS shares plunged more than 80% from their all-time high. The company is growing at a very fast pace and has a very strong balance sheet.
- 10/25/2022
|
Down 21.5% in 4 Weeks, Here's Why Hims & Hers Health, Inc. (HIMS) Looks Ripe for a Turnaround
- Hims & Hers Health, Inc. (HIMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 10/25/2022
|
Hims & Hers: The Market Has Lost Its Mind
- Hims & Hers has been beset by unrelenting selling pressure since it reached all-time highs last year. This has come against financial results that continue to outperform consensus estimates.
- 10/21/2022
|
Hims & Hers to Announce Third Quarter 2022 Earnings on November 7, 2022
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will report third quarter 2022 financial results after the market closes on Monday, November 7, 2022.
- 10/17/2022
|
Hims & Hers: Just What The Doctor Ordered
- Hims & Hers has now reported back-to-back quarters with over 100K net new subscriptions. The telehealth platform expects to approach a $540 million annual sales run rate in Q4.
- 09/16/2022
|
Teladoc Health Gains on Amazon Care's Loss. These Stocks Are Also Rising.
- Amazon will shut down its healthcare service business. Telehealth stocks are rising Thursday.
- 08/25/2022
|
Hims & Hers: Here's A Prescription For Portfolio Dysfunction
- Direct-to-patient healthcare is the future. H&H's mission is to make healthcare accessible, affordable, and convenient for everyone.
- 08/19/2022
|
Up 109% In 3 Months, This Monster Growth Stock Isn't Done Climbing Yet
- There's more where that came from.
- 08/17/2022
|
Hims & Hers CEO: We deliver health care at prices that are ‘cheaper than insurance'
- #Hims&HersCEO Hims & Hers Founder & CEO Andrew Dudum joins Yahoo Finance Live to discuss health care costs and birth control access in a post-Roe world.
- 08/09/2022
|
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q2 2022 Results - Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Jay Spitzer - Senior Vice President, Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Dan Grosslight - Citigroup Charlotte Kolb - Bank of America Jessica Tassan - Piper Sandler Maxi Ma - Deutsche Bank Jack Wallace - Guggenheim Securities Ivan Feinseth - Tigress Financial Joy Zhang - SVB Securities Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your operator today.
- 08/08/2022
|
This Stock Is Up 30% in 1 Month, With More Upside Ahead
- What stock soars 30% in this market? Hims & Hers.
- 08/02/2022
|
Hims & Hers Health: Promising Return Profile
- Hims is a stock which the market has punished beyond what is rational. The company is progressing nicely towards profitability and the share price should begin to creep up. The company's value proposition will lead to a solid moat. The company's effort to vertically integrate will expedite this process.
- 07/17/2022
|
This Former SPAC Looks Recession-Proof
- Hims & Hers has the growth and the cash to last.
- 06/20/2022
|
3 Top Stocks To Watch Before Next Week
- Penny stocks to watch right now. The post 3 Top Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/17/2022
|
7 Penny Stocks That Actually Have Analyst Buy Ratings
- Many penny stocks (stocks trading for less than $5 per share) have little analyst coverage, but these seven have sell-side "buy" ratings. The post 7 Penny Stocks That Actually Have Analyst Buy Ratings appeared first on InvestorPlace.
- 06/14/2022
|
Hims & Hers Health: Undervalued Company With Tremendous Upside
- Hims is a rapidly growing Telehealth company, which is providing significant value to its customers. The business has more positives going for it than negatives. The ever-declining stock price doesn't reflect the solid business behind it. The stock is in a free fall with no bottom in sight; however, that trend should reverse sharply.
- 06/12/2022
|
Hims & Hers: Improving Fundamentals + Declining Price = A Generational Buy
- In this note, we will discuss Hims & Hers' Q1 2022 report. Hims & Hers is delivering exceptional numbers on almost all KPI metrics. The stock keeps going lower, but the fundamentals are improving with each passing quarter.
- 05/16/2022
|
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q1 2022 Results - Earnings Call Transcript
- Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Jay Spitzer - Senior Vice President and Investor Relations Andrew Dudum - Co-Founder and our Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Daniel Grosslight - Citigroup Michael Cherny - Bank of America Jack Wallace - Guggenheim Jessica Tassan - Piper Sandler Operator Good afternoon. My name is Emma, and I will be your conference operator today.
- 05/09/2022
|
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates
- Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 11.11% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Hims & Hers Health: 3 Keys to Earnings
- Big things could be happening at this telehealth company.
- 05/04/2022
|
Will Hims & Hers Health, Inc. (HIMS) Report Negative Earnings Next Week? What You Should Know
- Hims & Hers Health, Inc. (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/02/2022
|
3 Things About Hims & Hers Health That Smart Investors Know
- Hims & Hers is a young company with a bright future ahead.
- 04/19/2022
|
Down 40% In Q1, Yet I'm Doubling Down On My Top Ideas For 2022
- My top ideas for 2022 plummeted by 40% on average in Q1 as high-growth tech stocks remain in a violent bear market amid multi-decade high inflation and a hawkish Fed.
- 04/12/2022
|
This Telehealth Stock's Rapid Product Launches Should Benefit Investors
- Hims and Hers is rapidly expanding its brand across multiple healthcare categories.
- 04/01/2022
|
Hims & Hers Health: The Updated Valuation Article
- Hims & Hers Health: The Updated Valuation Article
- 03/22/2022
|
Hims & Hers Health: A No-Brainer
- HIMS is on the path to profitability within the next few years. Investors have the opportunity to buy in early.
- 03/17/2022
|
7 Cheap Stocks to Buy If You Only Have $100 to Spend
- You can find many good stocks to buy for under $10. And here are seven cheap stocks that are good buys even if you only have $100 to spend.
- 03/11/2022
|
Top 3 Cheap Healthcare Stocks You Shouldn't Ignore.
- Some popular names in the healthcare sector have been down even by about 50% from their highs recently. But there are lots of opportunities in this sector.
- 02/26/2022
|
Best Penny Stocks To Buy The Dip? 4 With Unusual Options Activty Today
- Stock with unusual options activity today The post Best Penny Stocks To Buy The Dip? 4 With Unusual Options Activty Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/24/2022
|
Penny Stocks to Watch as Russia Ukraine Conflict Intensifies
- Are these penny stocks on your list as geopolitical tensions intensify? The post Penny Stocks to Watch as Russia Ukraine Conflict Intensifies appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/23/2022
|
Russian Stocks: What's Going on With SBRCY, YNDX, OGZPY, NOVKY and LUKOY Today?
- Russian stocks are on the move today with several shares taking a massive beating on Wednesday and we're diving into that news. The post Russian Stocks: What's Going on With SBRCY, YNDX, OGZPY, NOVKY and LUKOY Today?
- 02/23/2022
|
HIMS Stock: 12 Reasons Why Hims & Hers Shares Are Soaring Today
- Hims & Hers Health (HIMS) stock is soaring higher on Wednesday thanks to the company's earnings report for the fourth quarter of 2021. The post HIMS Stock: 12 Reasons Why Hims & Hers Shares Are Soaring Today appeared first on InvestorPlace.
- 02/23/2022
|
Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates
- Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -10% and 11.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/22/2022
|
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q4 2021 Results - Earnings Call Transcript
- Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q4 2021 Results - Earnings Call Transcript
- 02/22/2022
|
Hims & Hers shares pop 13% on big sales jump
- Hims & Hers Health Inc.'s HIMS, -4.55% stock jumped 13% in extended trading Tuesday after the company reported fiscal fourth-quarter revenue that exceeded Wall Street analysts' forecasts. Hims & Hers reported a net loss of $31.2 million, compared with a net loss of $5.2 million in the year-ago quarter.
- 02/22/2022
|
GNC Holdings To Offer Hims & Hers Products Through Select Stores, Online
- Hims & Hers Health Inc (NYSE: HIMS) has partnered with health and wellness brand GNC Holdings LLC to offer consumers health and wellness solutions at select GNC stores and online at GNC.com. "Our mass retail expansion is about building a trusted, nationwide brand for health and wellness products," said Melissa Baird, COO of Hims & Hers.
- 02/15/2022
|
HIMS: Great Buying Opportunity
- In 2018, Hims & Hers generated $27M and three years later it's already increased revenues by 10-fold, yet the company's trading at less than its 2019 valuation. Hims & Hers Health is a rapidly growing telehealth company that's disrupting the $4T US healthcare industry with its modern platform.
- 02/08/2022
|
Telehealth Stocks Suffered Severe Growing Pains in Past Year
- At the height of the pandemic, telehealth stocks became all the rage as investors concluded that virtual visits would take off since in-person consultations with a physician would be too risky.
- 02/03/2022
|
10 Top Penny Stocks To Buy Under $5 That Are Household Names
- Are these household stocks under $5 on your watch list in 2022? The post 10 Top Penny Stocks To Buy Under $5 That Are Household Names appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/26/2022
|
LifeMD: High Growth Telehealth Company Nearing Profitability
- LifeMD: High Growth Telehealth Company Nearing Profitability
- 01/26/2022
|
Hims & Hers Launches Hair Care Products At Select Walmart Locations
- Hims & Hers Health Inc (NYSE: HIMS) reported the availability of hair care solutions at select Walmart Inc (NYSE: WMT) retail locations nationwide and on Walmart.com starting this weekend. "We are thrilled to collaborate with such a well-known, household name such as Walmart as a continuation of our strategy to bring access to our products to consumers wherever they are across the country," said COO Melissa Baird.
- 01/20/2022
|
Digitally-Native Hims & Hers Health Adds Walmart To Its 10,000+ Strong Base Of Retail Doors
- Hims & Hers Health opens in Walmart, expanding its reach to over 11,000 retail doors. As a company that aims to be the front door to healthcare, it counts on exposure in retail to lead customers back to its full range of healthcare products and services.
- 01/20/2022
|
Hims & Hers, Walmart Bring Hair Care Products to 1,400+ Stores
- Telehealth platform Hims & Hers is launching its line of hair care solutions at more than 1,400 Walmart retail locations nationwide and on walmart.com, according to a Thursday (Jan. 20) press release. The products will be available beginning this weekend.
- 01/20/2022
|
Hims & Hers Names Yemi Okupe As Finance Chief
- Hims & Hers Health Inc (NYSE: HIMS) has appointed Yemi Okupe as its Chief Financial Officer, effective January 24, 2022. From 2019 to 2021, Okupe served as a Divisional CFO at Uber Technologies Inc (NYSE: UBER), first in charge of UberEats and later of Uber's global mobility unit.
- 01/19/2022
|
3 Top Healthcare Stocks to Buy for January
- Healthcare is a massive industry, and opportunities are everywhere.
- 01/08/2022
|
My Top 5 Stock Ideas For 2022
- Inflation is hitting multi-decade highs, causing investor panic in equity markets. Although broader indices do not reflect this panic, several growth stocks are down ~40-80% from their highs. After a violent valuation reset in the growth stock universe, long-term investors are operating in a fearful market environment with generational opportunities abound.
- 12/27/2021
|
Hims & Hers: Massively Undervalued Compared With Ro
- H&H's closest competitor is Ro. Both companies have similar business models but different acquisition strategies.
- 12/20/2021
|
3 No-Brainer Stocks I'd Buy Right Now Without Hesitation
- Buying quality stocks when they dip can make you money over the long term.
- 12/11/2021
|
Hims & Hers Health: The Valuation Article
- Hims & Hers is a company that should be considered by investors who are looking for a speculative stock with favorable risk to reward ratio. The market is pricing Him & Hers as if its story is nearing its end when in reality, we haven't even finished the first chapter.
- 12/09/2021
|
UBER Teams Up With Hims & Hers to Deliver Personal Care Products
- UBER expands its delivery network, partnering with Hims & Hers to offer on-demand delivery of personal wellness products to customers across the United States.
- 11/30/2021
|
Uber Eats partners with Hims & Hers, will deliver in 12 markets
- Uber wants in on the health and wellness space. The rideshare and food delivery giant is partnering with telehealth platform Hims & Hers (NYSE: HIMS) to deliver personal care and health products to Uber Eats customers in 12 markets, including Los Angeles, Seattle, Miami, Philadelphia and Austin, Texas.
- 11/30/2021
|
Hims & Hers Health Inks On-Demand Delivery Partnership With Uber
- Hims & Hers Health Inc (NYSE: HIMS) entered an on-demand delivery partnership with Uber Technologies Inc (NYSE: UBER) to bring its personal care products to customers through the Uber Eats app. The financial terms of the arrangement were not disclosed.
- 11/29/2021
|
Hims & Hers Health (HIMS) Stock: $12 Price Target From Piper Sandler
- The shares of Hims & Hers Health Inc (NYSE: HIMS) have received a price target of $12 from Piper Sandler. These are the details.
- 11/16/2021
|
Hims & Hers: Eventually The Ugly Duckling Becomes A Beautiful Swan
- Hims & Hers: Eventually The Ugly Duckling Becomes A Beautiful Swan
- 11/15/2021
|
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q3 2021 Results - Earnings Call Transcript
- Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Hims & Hers Health, Inc. to Announce Third Quarter 2021 Financial Results and Host Conference Call
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, will release fiscal third quarter financial results on Wednesday, November 10, 2021 after market close, with a conference call to follow at 5:00 p.m. E.T. Conference Call Details The conference call can be accessed by dialing (833) 900-2256 for U.S. participants and (236) 714-2
- 10/27/2021
|
This Under-the-Radar Healthcare Stock Might Be on Sale for the Last Time
- Investors are skeptical of Hims & Hers, pushing the stock back toward 52-week lows during September's sell-off. But are they right?
- 10/16/2021
|
Hims & Hers hair products now available at Vitamin Shoppe locations
- Wellness and telehealth company Hims & Hers Health Inc. HIMS, +2.03% said Monday that its haircare products will now be available at 280 Vitamin Shoppe locations and on the retailer's website. Vitamin Shoppe is a subsidiary of Franchise Group Inc. FRG, -1.36%.
- 10/11/2021
|
Vitamin Shoppe To Offer Haircare Products From Hims & Hers
- Hims & Hers Health Inc (NYSE: HIMS) has partnered with The Vitamin Shoppe , a subsidiary of Franchise Group Inc (NASDAQ: FRG), to make its products available on the latter's platform. The financial terms of the arrangement remain undisclosed.
- 10/11/2021
|
Hims & Hers: Subscription Health Re-Evaluated
- Hims & Hers is back to reporting impressive revenue growth near 70%.
- 09/24/2021
|
Hims & Hers Health: An Amazing Bargain Price For This High Growth Stock
- As high-growth names start to make a comeback, investors would do well to consider this healthcare stock. Hims is likely to smash through its 30% revenue growth rate expectations in 2022.
- 09/23/2021
|
Hims & Hers Launches Supplement Powder To Support Urinary Tract Health
- Hims & Hers Health Inc (NYSE: HIMS) has expanded its women's health offerings by launching a D-Mannose dietary supplement powder to support urinary tract health on ForHers.com. The supplement powder comes in packages of 10 cranberry-raspberry flavored single-serve packets.
- 09/16/2021
|
3 Stocks You'll Be Glad You Bought at These Prices
- New companies in U.S. healthcare are bringing innovative, positive solutions to consumers.
- 09/15/2021
|
E-commerce fashion site Revolve adds health products from Hims & Hers
- Hims & Hers Health Inc. HIMS, +1.04% said Wednesday that its products focused on skin and haircare, sleep and sexual health will now be available on the e-commerce fashion site Revolve. Revolve Group Inc. RVLV, +1.47% targets millennials and Gen Z.
- 09/15/2021
|
Revolve To Offer Hims & Hers Health Products
- Telehealth platform Hims & Hers Health Inc (NYSE: HIMS) has announced a partnership with Revolve Group Inc (NYSE: RVLV). Revolve will add a range of health and wellness solutions from Hims & Hers to its site, Revolve.com.
- 09/14/2021
|
3 High-Growth Healthcare Stocks to Buy in September
- All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.
- 09/09/2021
|
2 Top Growth Stocks That Beat Expectations and Raised Guidance
- Both grew their sales by more than 50% in their most recent quarters.
- 09/08/2021
|
Gronk Spike: Hims & Hers Signs Rob Gronkowski To Partnership
- One of the most well-known NFL players is partnering with a health care company to bring awareness to men's health issues and treatment. What Happened: Tampa Bay Buccaneers tight end Rob Gronkowski has signed a partnership with Hims & Hers Health Inc (NYSE: HIMS).
- 09/07/2021
|
Hims & Hers Health CFO To Step Down; Reaffirms Outlook
- Hims & Hers Health Inc (NYSE: HIMS) has announced that Spencer Lee will step down as its Chief Financial Officer. Lee will lead a six-month transition plan and continue to support the company until a new CFO is appointed to ensure a smooth transition.
- 09/07/2021
|
Hims & Hers Partners With Rob Gronkowski to Bring Awareness to Men's Health Issues and Treatment
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers partners with Rob Gronkowski to bring awareness to men's health issues and treatment.
- 09/07/2021
|
Time To Buy Hims & Hers
- Hims & Hers is a consumer healthcare brand targeting young digitally native consumers and stigmatized disorders. Hims & Hers management is building a track record of strong growth, scalability, and underpromising and overdelivering.
- 08/25/2021
|
Hims & Hers Stock: Trading At All-Time Lows, Worth Considering A Buy
- The stock now trades at an all-time low. Investors are too fearful to even consider this stock. Meanwhile, Hims & Hers continues to grow at a strong rate, with impressive guidance ahead.
- 08/18/2021
|
What the Market Is Missing About Hims & Hers Health
- This stock's share price is not matching up with the company's underlying performance. Let's investigate.
- 08/17/2021
|
Why Hims & Hers Health Fell by Nearly 11% Today
- New week, new price target decrease from an analyst.
- 08/16/2021
|
Hims & Hers CFO on telehealth: There's a ‘ton of demand' in the market
- Spencer Lee, CFO of Hims & Hers, joins Yahoo Finance Live to discuss the company's strong second-quarter results and breakdown what the future of telehealth looks like post-COVID. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
- 08/13/2021
|
Why Hims & Hers Health Shares Are Trading Higher Today
- Hims & Hers Health Inc (NYSE: HIMS) is trading higher Thursday after the company announced better-than-expected second-quarter financial results and issued guidance above estimates. Hims & Hers Health reported a quarterly earnings loss of 5 cents per share, which beat the estimate for a loss of 10 cents per share.
- 08/12/2021
|
Why Hims & Hers Health Stock Popped Today
- Shares of the telehealth company rose on better-than-expected second-quarter results.
- 08/12/2021
|
Hims & Hers Stock Shoot Up - What You Need To Know
- A multi-specialty telehealth platform provider, Hims & Hers Health Inc (NYSE: HIMS), reported Q2 sales increased 69% Y/Y to $60.7 million, beating the consensus of $56.49 million. "This was a quarter of very strong execution, as we continued to drive consistent organic revenue growth across our business, from our core categories to the newer mental health services," said Andrew Dudum, CEO and co-founder.
- 08/12/2021
|
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q2 2021 Results - Earnings Call Transcript
- Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
What's Going On With Hims & Hers Health's Stock After Hours?
- Hims & Hers Health Inc (NYSE: HIMS) shares are trading higher by 13.1% at $8.48 in Wednesday's after-hours session after the company reported better-than-expected second-quarter EPS and sales results and issued third-quarter 2021 revenue guidance above estimates. Hims & Hers Health reported quarterly losses of 5 cents per share which beat the analyst consensus estimate of a loss of 10 cents per share.
- 08/11/2021
|
Hims & Hers stock jumps 12% on better-than-expected revenue, earnings
- Shares of Hims & Hers Health Inc. HIMS, -3.44% jumped 12% in extended trading Wednesday after the health-care company reported fiscal second-quarter results. Hims & Hers reported a net loss of $9.1 million, or 5 cents a share, compared with a net loss of $927,000, or 3 cents a share, in the year-ago quarter.
- 08/11/2021
|
Hims & Hers: Collapse Comes With Risks And Opportunities For Its Investors
- Hims & Hers common shares have fallen materially in recent months and its new price presents an opportunity to reevaluate the company. The company is on track to hit total revenue for fiscal 2021 of at least $221 million. It also sports a high gross profit margin.
- 08/07/2021
|
The Pandemic's Impact on Americans' Mental Health: New Hims & Hers Survey Shows 70% Remain Anxious Around Post-Pandemic ‘Normal', Half Have Considered Therapy for the First Time
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers releases survey findings on the pandemic's impact on Americans' mental health.
- 07/13/2021
|
Hims & Hers Announces Redemption of All Outstanding Warrants
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will redeem all of its outstanding warrants (the “Warrants”) to purchase shares of the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”), that were issued under the Warrant Agreement, dated July 22, 2019 (t
- 07/09/2021
|
Hims & Hers Completes Acquisition of Apostrophe
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers has finalized the acquisition of teledermatology specialist, Apostrophe.
- 07/07/2021
|
Why This Hims Analyst Sees Strong Growth Potential In Highly Competitive Market
- The potential for expansion coupled with a highly competitive pharmacy market has a BofA Securities analyst sidelined on shares of Hims & Hers Health, Inc. (NYSE:HIMS). The Hims Analyst: Michael Cherny initiated coverage on shares of Hims & Hers Health, Inc. with a Neutral rating and $12 price target.
- 07/06/2021
|
Urban Outfitters' (URBN) Alliance With Hims & Hers Augurs Well
- Urban Outfitters (URBN) partners with Hims & Hers Health to offer personalized wellness offerings to customers.
- 07/01/2021
|
3 Growth Stocks That Took a Big Hit This Week
- The stock price for each of these companies dropped more than 5% on Tuesday.
- 06/16/2021
|
Hims & Hers To Acquire Honest Health, Expand UK Foothold
- Multispecialty telehealth platform Hims & Hers will acquire London-based health program Honest Health, which works in hair-loss-related products, a press release said Monday (June 14). With the acquisition, Hims & Hers will expand its London offering.
- 06/14/2021
|
Telehealth company Hims & Hers to buy U.K.'s Honest Health
- Telehealth company Hims & Hers Health Inc. said late Monday it has agreed to buy London-based health platform Honest Health for an undisclosed amount. Honest Health offers hair loss-related products, including access to compounded products.
- 06/14/2021
|
Hims & Hers: Riding The DTC Telehealth Wave
- Hims & Hers enjoyed massive tailwinds as a result of the pandemic, and it should stay that way when the dust settles. It is still a relatively young company and still has many growth initiatives to disrupt the centuries-old healthcare industry.
- 06/04/2021
|
9 SPACs to Buy After the Selloff
- Following their sector-wide correction, shares in these nine SPACs and former SPACs have fallen to an attractive entry point. The post 9 SPACs to Buy After the Selloff appeared first on InvestorPlace.
- 05/27/2021
|
Here's the Top Under-the-Radar Telemedicine Stock to Buy Now
- Looking for cheap telemedicine stocks on the move? Look no further.
- 05/25/2021
|
Hims & Hers Health, Inc. to Host Virtual Annual Meeting of Shareholders
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will hold its virtual annual meeting of shareholders on June 17, 2021 at 10:00 a.m. Pacific Time. A live audio webcast of the meeting will be available online at https://investors.forhims.com/. Shareholders who wish to participate can access the meeting at www.virtualshareholdermeeting.com/HIMS2021. In o
- 05/17/2021
|
Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)
- SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today announced that, as a result of guidance provided by the Staff of the Securities and Exchange Commission (the “SEC”) on April 12, 2021 for all SPAC-related companies regarding the accounting and reporting for their warrants, it will restate the 2020 and 2019 consolidated financial statements previou
- 05/04/2021
|
Hims & Hers Health Can Regrow Hair With Thicc Margins
- Hims & Hers Inc. is the proof-of-concept that healthcare doesn't have to suck. Customers are loving it, with revenue growing from $0 to $149M in 36 months.
- 04/28/2021
|
Trouble Ahead For Hims & Hers Stock?
- Shares of Hims & Hers Health, Inc. (NYSE:HIMS) are in trouble. The stock is testing critical support and if this support holds, shares may rally.
- 04/16/2021
|
3 Top Recent IPO Stocks to Buy Now
- Here are three companies with exciting growth stories that just went public.
- 04/15/2021
|
3 Top Healthcare Growth Stocks to Buy for April
- These companies are at the forefront of innovation in the healthcare sector, and their stocks are surprisingly affordable too.
- 04/10/2021
|
Buy Hims & Hers As It Falls Back Toward Prior Lows
- Ignore the near-term pullback in Hims & Hers. With its unique business model, telehealth play HIMS stock remains a potential long-term winner.
- 04/01/2021
|
Hims & Hers CEO on portfolio expansion opportunities, company outlook
- Yahoo Finance's Brian Sozzi, Myles Udland, and Julie Hyman speak with Hims & Hers Co-founder & CEO Andrew Dudum about the company's first earnings report since going public.
- 03/23/2021
|
Why Hims & Hers Health Stock Was Falling Today
- Shares of the newly public company dropped on weak guidance in its fourth-quarter earnings report.
- 03/19/2021
|
Hims & Hers Health, Inc Revenue Jumps 67 Pct
- Multi-specialty telehealth platform Hims & Hers Health, Inc. reported that revenue surged 67 percent from the fourth quarter of 2019 to the fourth quarter of 2020. “This is an organization built on solid fundamentals and favorable business characteristics and I'm incredibly confident in our ability to deliver on our vision of helping more people with a wider range […]
- 03/19/2021
|
Hims & Hers reports £3.73 million of net loss in the fourth quarter
- Hims & Hers Health Inc. (NYSE: HIMS) reported its financial results for the fiscal fourth quarter on Thursday that came in better than what analysts had anticipated, despite the ongoing Coronavirus pandemic that has so far infected more than 30 million people in the United States and caused over half a million deaths. Hims & […] The post Hims & Hers reports £3.73 million of net loss in the fourth quarter appeared first on Invezz.
- 03/19/2021
|
Hims & Hers stock dips 8% despite big hike in sales
- Shares of Hims & Hers Health Inc. were down 8% in extended trading Thursday after the telehealth-consultation company announced fiscal fourth-quarter results. Hims & Hers reported a net loss of $5.2 million, compared with a net loss of $12.4 million in the year-ago quarter.
- 03/18/2021
|
Hims & Hers Appoints Two New Board Members
- SAN FRANCISCO--(BUSINESS WIRE)--Andrea Perez and Ambar Bhattacharyya join Hims & Hers Board of Directors to help the company pioneer a better way for patients to access healthcare.
- 03/10/2021
|
This DTC Telemedicine Stock Has Enormous Potential Thanks to the $12 TRILLION Digital Healthcare Revolution
- A small company by the name of Conversion Labs (NASDAQ:CVLB) will be the eBay or Alibaba of the DTC telemedicine platforms space. The post This DTC Telemedicine Stock Has Enormous Potential Thanks to the $12 TRILLION Digital Healthcare Revolution appeared first on InvestorPlace.
- 02/19/2021
|
3 of the Latest Companies to Go Public Via SPACs
- SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.
- 02/17/2021
|
Hims & Hers Stock Sits Where This Market Is Headed
- Telehealth is the future, and Hims & Hers looks well-positioned for that future. Growth should keep the rally in HIMS stock going.
- 02/17/2021
|
Is Hims & Hers Health a Good Way To Play the Telehealth Megatrend?
- The prospects for HIMS stock look good. The company has certainly built a robust platform.
- 02/15/2021
|
As It Moves Goes Big on Telehealth, Hims & Hers Health Is a Buy on a Pull Back
- If you believe in the future of telemedicine, then keep an eye on HIMS stock. It might not be in the buy zone yet, though, so be patient.
- 02/09/2021
|
What's Better? 1 Share of GameStop or 13 of Hims & Hers Health?
- You can buy one share of GameStop or 13 shares of Hims & Hers Health. The smart money is buying HIMS stock at current prices.
- 02/01/2021
|
Hims & Hers: A Digital Front Door To The Healthcare System
- Hims & Hers: A Digital Front Door To The Healthcare System
- 02/01/2021
|
HIMS Stock Price Increases Over 25% Pre-Market: Why It Happened
- The stock price of Hims & Hers Health Inc (NYSE: HIMS) has increased by over 25% pre-market today. This is why it happened.
- 01/28/2021
|
Buy Hims & Hers Stock for a Solid Play on Telehealth
- With its focus on millennials, fast growing telemedicine play HIMS stock has plenty of room to run after its recent SPAC merger. The post Buy Hims & Hers Stock for a Solid Play on Telehealth appeared first on InvestorPlace.
- 01/26/2021
|
Hims & Hers CEO on $1.6 billion SPAC deal and goal to provide affordable health care
- Hims & Hers Co-Founder and CEO Andrew Dudum joins Yahoo Finance's Brain Sozzi and Julie Hyman to discuss the company's $1.6 billion SPAC deal with Oaktree Capital Management and discuss the future of medicine and telehealth. For 2020 election results please visit: Election results: https://www.yahoo.com/elections Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
- 01/24/2021
|
HIMS Stock: 12 Things to Know as Telehealth Play Hims & Hers Starts Trading
- Telehealth play HIMS stock makes its debut today. Here's what you should know about newly public Hims & Hers now.
- 01/21/2021
|
